{"Environment": ["Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.", "We  are  directly  exposed  to  market  price  changes  for  certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex.  We  typically  purchase  raw  materials  at  either  market  prices  or prices  tied  to  a  commodity  index  and  some  finished  goods  at  prices based in part on a commodity price index.", "Environmental, Health and Safety Laws In  the  United  States  and  other  countries,  we  are  subject  to  various federal,  state  and  local  environmental  laws,  including  laws  regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.", "Industry  participants,  including  us,  rely  on  ethylene  oxide  (\u201cEtO\u201d)  to sterilize  certain  medical  products  that  we  manufacture  or  distribute.", "Regulatory  actions  have  been  taken  by  certain  environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process.", "If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide  supply  shortages  or  a  reduction  in  surgical  or  medical procedures.  Such  increased  costs  or  industry-wide  reductions  in surgical and medical procedures would have a negative impact on our Medical segment profit.", "Prices of oil and gas also affect our distribution and transportation costs.", "Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials.", "Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs."], "Social": ["These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law.", "These measures are considered \u201cnon-GAAP financial measures\u201d  under  the  Securities  and  Exchange  Commission  (\u201cSEC\u201d)  rules.  The  reasons  we  use  these  non-GAAP  financial  measures  and  the reconciliations  to  their  most  directly  comparable  GAAP  financial  measures  are  included  in  the  \u201cExplanation  and  Reconciliation  of  Non-GAAP Financial Measures\u201d section following MD&A in this report.", "Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020.", "These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.", "Forward-looking statements in this report speak only as of the date of this document.", "Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.", "The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.", "We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.", "The sum of the components and certain computations may reflect rounding adjustments.", "We  had  GAAP  operating  earnings  of  $472  million  and  a  GAAP  operating  loss  of  $4.1  billion  during  fiscal  2021  and  2020,  respectively,  which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications.", "(3) For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self- insurance  pre-tax  loss  related  to  opioid  litigation  claims  versus  separate  tax  adjustments.  The  tax  benefit  allocated  to  the  separate  tax  adjustments  of  $35  million  is included in non-GAAP measures.", "The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.", "Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020.", "COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020.", "We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.", "As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products.", "We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above.", "As a result,  in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive.", "However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow.", "Its impact may be greater or less than we anticipate.", "In  July  2021,  we  announced  that  we  and  two  other  national  distributors  have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions  are  satisfied  (including  Boards  of  Directors'  approval),  would  result  in  the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.", "West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups.", "In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State  of  New  York  and  its  participating  subdivisions.  If  the  Proposed  Settlement  Agreement  becomes  effective,  New  York  and  its  participating subdivisions will become a part of it.", "It is possible  that  a  sufficient  number  of  states  and  subdivisions  will  not  agree  to  the  Proposed  Settlement  Agreement  or  that  other  required contingencies will not be satisfied.", "If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief  terms  relating  to  settling  distributors\u2019  controlled  substance  anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring.", "In  connection  with  the  opioid  lawsuits  and  settlement  negotiations,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and  $5.63  billion  in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively.", "In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before  September  30,  2021,  and  the  remainder  is  included  in  deferred  income  taxes  and  other  liabilities  in  the  consolidated  balance  sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and  unfavorable  developments  or  resolutions  can  occur,  the  assessment  is  highly subjective  and  requires  judgments  about  future  events.  We  regularly  review  these  opioid  litigation  matters  to  determine  whether  our  accrual  is adequate.", "The amount of ultimate loss may differ materially from this accrual.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change.", "The actual amount or timing of the tax benefit may differ from these expectations.", "On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and  claims  related  to  inferior  vena  cava  (\"IVC\")  filters  in  the  U.S.  and  Canada  as  described  in Note  7 of  the  \u201cNotes  to  Consolidated  Financial Statements.\u201d The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred.", "We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.", "In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities.", "We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022.", "We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.", "For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.", "In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029.", "We expect that these investments will result in increased project-related  expenses and depreciation related to capital expenditures,  which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact.", "Impairments and (Gain)/Loss on Disposal of Assets, Net During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business.", "Litigation (Recoveries)/Charges, Net During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters.", "During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.", "During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.", "The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement.", "Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates.", "Ongoing Audits We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions.", "With few exceptions, we are  subject  to  audit  by  taxing  authorities  for  fiscal  years  2015  through  the  current  fiscal  year.  Tax  laws  are  complex  and  subject  to  varying interpretations.", "During fiscal 2021, we resolved all open issues with respect to the Company\u2019s activity within fiscal years 2008 through 2014 with the U.S.", "This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years.", "New challenges related to future audits may adversely affect our effective tax rate or tax payments.", "We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion;  contractual  obligations;  tax  payments;  current  and  projected  debt  service  requirements,  early  extinguishment  of  debt,  dividends  and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement.", "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.", "Our  cash and equivalents  balance was  $3.4 billion at  June 30,  2021 compared to $2.8 billion at June 30, 2020.", "During  fiscal  2020,  our  cash  and  equivalents  increased  due  to  $2.0 billion  of  net  cash  provided  by  operating  activities,  which  reflects increases to working capital associated with the timing of payments to vendors,  and  $886  million  of  net  cash  proceeds  from  the  sale  of investments,  substantially  all  of  which  was  related  to  the  sale  of  our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.", "Credit Facilities and Commercial Paper In  addition  to  cash  and  equivalents  and  operating  cash  flow,  other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper  program,  backed  by  a  $2.0  billion  revolving  credit  facility.  We also  have  a  $1.0  billion  committed  receivables  sales  facility.  At June 30, 2021, we had no amounts outstanding under our commercial paper  program,  revolving  credit  facility  or  our  committed  receivables sales facility.", "During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total  daily  amounts  outstanding  of  $200  million  and  an  immaterial average combined daily amount outstanding.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "In  June  2021,  we  returned  $127  million  of  cash  held  by  foreign subsidiaries to the U.S.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "Long-Term Obligations At  June  30,  2021,  we  had  total  long-term  obligations,  including  the current portion and other short-term borrowings of $6.2 billion.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption", "price  equal to 100% of  the  principal  amount  and accrued  but  unpaid interest,  plus  the  make-whole  premium  applicable  to  the  notes.  In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  these  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on", "Risk Management We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability.", "We also use interest  rate  swaps  to  protect  the  value  of  our  debt  and  use  foreign currency  forward  contracts  to  protect  the  value  of  our  existing  and forecasted foreign currency assets and liabilities.", "We  expect  capital  expenditures  in  fiscal  2022  to  be  between  $400 million and $450 million and to be primarily for information technology and infrastructure projects.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain  liabilities.  The  transaction  closed  on  August  2,  2021  and  we received proceeds of $927 million, net of cash transferred.", "Dividends During  fiscal  2021,  we  paid  quarterly  dividends  totaling  $1.94  per share, an increase of 1 percent from fiscal 2020.", "On  August  4,  2021,  our  Board  of  Directors  approved  a  quarterly dividend  of  $0.4908  per  share,  payable  on  October  15,  2021  to shareholders of record on October 1, 2021.", "Share Repurchases During fiscal 2021 and 2020, we repurchased $200 million and $350 million,  respectively,  of  our  common  shares.  We  funded  the repurchases with available cash and short-term borrowings.", "(1) Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below.", "variable  price  provisions;  and  approximate  timing  of  the  transaction.  The purchase  obligation  amounts  disclosed  above  represent  estimates  of  the minimum for which we are obligated and the time period in which cash outflows will occur.", "Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table.", "In addition, contracts  that  can  be  unilaterally  canceled  with  no  termination  fee  or  with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased  during the requisite notice period.", "We currently expect to make our first annual  settlement  payment  of $405 million into escrow on or before September 30, 2021.", "If the settlement agreement does not become effective, this payment will be returned to us.", "We expect subsequent annual payments to be made beginning in July 2022.", "Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and  (ii)  require  the  use  of  complex  and  subjective  estimates  based  upon  past  experience  and  management\u2019s  judgment.  Other  people  applying reasonable judgment to the same facts and circumstances could develop different estimates.", "Because estimates are inherently uncertain, actual results may differ.", "In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions.", "The  allowance  for  doubtful  accounts  includes  general  and  specific reserves.  We  determine  our  allowance  for  doubtful  accounts  by reviewing  accounts  receivable  aging,  historical  write-off  trends, payment history, industry trends, customer financial strength, customer credit  ratings  or bankruptcies.  We regularly  evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic,  may  affect  credit  risks.  See Note  1 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further information on our policy for Receivables and Allowance for Doubtful Accounts.", "We believe the reserve  maintained  and  expenses  recorded  in  fiscal  2021  are appropriate.", "At this time, we are not aware of any analytical findings or customer issues  that  are  likely  to  lead  to  a  significant  future  increase  in  the allowance  for  doubtful  accounts  as  a  percentage  of  revenue.  In addition, the Financial Accounting Standards Board\u2019s", "The  LIFO  impact  on  the  consolidated  statements  of  earnings/(loss) depends  on  pharmaceutical  manufacturer  price  appreciation  or deflation  and  our  fiscal  year-end  inventory  levels,  which  can  be meaningfully  influenced  by  customer  buying  behavior  immediately preceding  our  fiscal  year-end.  Historically,  prices  for  branded pharmaceuticals have generally tended to rise, resulting in an increase in  cost  of  products  sold,  whereas  prices  for  generic  pharmaceuticals generally  tend  to  decline,  resulting  in  a  decrease  in  cost  of  products sold.", "This guidance did not have a material impact on our  consolidated  financial  statements  or  disclosures.  The  following table  presents  information  regarding  our  allowance  for  doubtful accounts over the past three fiscal years:", "Using  LIFO,  if  there  is  a  decrease  in  inventory  levels  that  have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held  at  a  lower  cost.  Conversely,  if  there  is  a  decrease  in  inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.", "The sum of the components may not equal the total due to rounding.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "Purchased  goodwill  and  intangible  assets  with  indefinite  lives  are tested for impairment annually or when indicators of impairment exist.", "We have elected to bypass the qualitative  assessment  for  the  annual  goodwill  impairment  test  in  the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments  are  comprised  of  divisions  (which  are  components),  for which  discrete  financial  information  is  available.  Components  are aggregated  into  reporting  units  for  purposes  of  goodwill  impairment testing  to the extent  that  they  share similar  economic  characteristics.", "COVID-19.  As  selling  prices  and  customer  demand  have  decreased compared  to  the  peak  of  COVID-19,  we  recorded  a  reserve  of $197 million, primarily related to certain categories of gloves, to reduce the  carrying  value  of  certain  PPE  to  its  net  realizable  value.  Our estimates for selling prices and demand are inherently uncertain and if our  assumptions  decline  in  the  future,  additional  inventory  reserves may be required.", "For example, a hypothetical 5 percent decline in the estimated  selling  prices  would  have  decreased  the  estimated  net realizable  value  of  our  inventory  by  approximately  $30  million  as  of June 30, 2021.", "Inventories presented in the consolidated  balance  sheets  are  net  of  reserves  for  excess  and obsolete  inventory  which  were  $185  million  and  $155  million  at June  30,  2021  and  2020,  respectively.  If  actual  conditions  are  less favorable than our assumptions, additional inventory reserves may be required.", "identification  of  reporting  units,  qualitative  evaluation  of  events  and circumstances  to  determine  if  it  is  more  likely  than  not  that  an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.", "Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using  discount  rates  ranging  from  8.5  percent  to  11.5  percent).  We use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed  forecasts.  Under  the  market-based  guideline public  company  method,  we  determine  fair  value  by  comparing  our reporting  units  to  similar  businesses  or  guideline  companies  whose securities  are  actively  traded  in  public  markets.  We  also  use  the market-based  guideline  transaction  method  to  determine  fair  value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "Estimating the fair value of reporting units requires the use of estimates and  significant  judgments  that  are  based  on  a  number  of  factors including actual operating results.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "Medical Unit Goodwill Due  to  the  planned  divestiture  of  our  Cordis  business,  we  allocated $388 million of  goodwill from  the  Medical  Unit  to the Cordis  disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.", "For  our  annual  impairment  test  in  fiscal  2021,  the  fair  value  of  the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent.", "For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent.  Additionally,  we  assigned  a  weighting  of  80  percent  to  the discounted  cash  flow  method,  10  percent  to  the  guideline  public company method, and 10 percent to the guideline transaction method.", "For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.", "If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.", "For any of  our  other  reporting  units,  the  fair  value  would  not  have  been  less than the carrying amount for fiscal 2021 if we increased the discount rate  by  1  percent  or  if  the  U.S.  federal  statutory  tax  rate  were  to increase to 28 percent.", "We  also  performed  goodwill  impairment  testing  during  the  three months ended March 31, 2021 for the portion of the Medical Unit that would be retained.", "There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.", "The impairment test for indefinite-lived intangibles other than goodwill (primarily  trademarks)  involves  first  assessing  qualitative  factors  to determine if it is more likely than not that the fair value of the indefinite- lived  intangible  asset  is  less  than  its  carrying  amount.  If  so,  then  a quantitative test is performed to compare the estimated fair value of the indefinite-lived  intangible  asset  to  the  respective  asset's  carrying amount.  Our  qualitative  evaluation  requires  the  use  of  estimates  and significant  judgments  and  considers  the  weight  of  evidence  and significance  of  all  identified  events  and  circumstances  and  most relevant drivers of fair value, both positive and negative, in determining whether  it  is  more  likely  than not  that  the  fair  value  of  the  indefinite- lived intangible asset is less than its carrying amount.", "In  connection  with  the  opioid  litigation  as  described  further  in  the Significant  Developments  in  Fiscal  2021  and  Trends  section  in  this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively.", "In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies.", "There  is  no  assurance  that  the  contingencies  to  the  proposed settlement agreement will be satisfied.", "We develop and periodically  update reserve  estimates  for  the Cordis IVC  claims,  including  those  received  to  date  and  expected  to  be received in the future and related costs.", "To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.", "Self-Insurance We  self-insure  through  a  wholly-owned  insurance  subsidiary  for employee  healthcare,  certain  product  liability  matters,  auto  liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.", "For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to  each  claim  if  available.  Other  estimates  are  based  on  an assessment  of  outstanding  claims,  historical  analysis  and  current payment trends.", "We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates  in the respective  jurisdictions  in which we operate.  Our  income tax  expense,  deferred  income  tax  assets  and  liabilities,  and unrecognized  tax  benefits  reflect  management\u2019s  assessment  of estimated future taxes to be paid on items in the consolidated financial statements.", "The following table presents information about our tax position at June 30:", "Expiring  or  unusable  loss  and  credit  carryforwards  and  the  required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be  realized.  After  applying  the  valuation  allowances,  we  do  not anticipate any limitations  on our use of any of the other net deferred income tax assets described above.", "and credit carryforwards for which the ultimate realization of future benefits is uncertain.", "We  regularly  review  contingencies  and  self-insurance  accruals  to determine whether our accruals and related disclosures are adequate.", "intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Tax Effects of Self-Insurance Pre-tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021.", "We  also  increased  our  non-current  deferred  tax  liability  by approximately $700 million during fiscal 2021 related to this matter.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded  a  tax  benefit  of  $228  million  and  $488  million,  respectively.", "Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.  The  fiscal  2021  net  tax  benefit  and  unrecognized  tax benefits were primarily due to our assessment of the specific terms of the  Proposed  Settlement  Agreement.  We  have  made  reasonable estimates  and  recorded  amounts  based  on  management's  judgment and  our  current  understanding  of  the  Tax  Act;  however,  these estimates require significant judgment since the U.S. tax law governing deductibility  was  changed  by  the  U.S.  Tax  Cuts  and  Jobs  Act  (\"Tax Act\").", "Further, it is possible that Congress or the tax authorities could challenge  our  interpretation  of  the  Tax  Act  or  the  estimates  and assumptions used to assess the future deductibility of these benefits.", "The actual amount of the tax benefit may differ materially from these estimates.  See Note  8 of  the  \u201cNotes  to  the  Consolidated  Financial Statements.\u201d We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "New challenges related to  future  audits  may  adversely  affect  our  effective  tax  rate  or  tax payments.", "Our assumptions and estimates around uncertain tax positions require significant  judgment;  the  actual  amount  of  tax  benefit  related  to uncertain tax positions may differ from these estimates.", "We  believe  that  our  estimates  for  the  valuation  allowances  against deferred  tax  assets  and  unrecognized  tax  benefits  are  appropriate based on current facts and circumstances.", "The amount we ultimately pay when matters are resolved may differ from the amounts accrued.", "unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets.", "For a further  discussion  on  Provision  for  Income  Taxes,  see Note  8 of  the \u201cNotes to the Consolidated Financial Statements.\u201d The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as  per  the  Tax  Act  as  enacted  by  the  United  States  government  on December  22,  2017.  We  have  made  reasonable  estimates  and recorded  amounts  based  on  management  judgment  and  our  current understanding of the Tax Act which is subject to further interpretation by  the  IRS.  See Note  8 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d for additional information.", "In  addition  to  analyzing  our  business  based  on  financial  information  prepared  in  accordance  with  GAAP,  we  use  these  non-GAAP  financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business.", "We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors.", "However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.", "The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior  to,  financial  measures  calculated  in  accordance  with  GAAP,  and  the  financial  results  calculated  in  accordance  with  GAAP  and reconciliations to those financial statements set forth below should be carefully evaluated.", "The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results.", "We did not recognize any LIFO charges or credits during the periods presented.", "Income from surgical gown recall costs represents insurance recoveries of these certain costs.", "We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies\u2019 financial results. \u2022 State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred.", "This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business.", "Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items.", "\u2022 Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.", "\u2022 Amortization  and  other  acquisition-related  costs,  which  include  transaction  costs,  integration  costs,  and  changes  in  the  fair  value  of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results.", "We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity\u2019s initial balance sheet as part of the purchase price allocation.", "These costs are also significantly impacted by the timing, complexity and size of acquisitions.", "The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.", "\u2022 Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.", "\u2022 Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.", "During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss.", "As a result, we allocated substantially all of the tax benefit to litigation charges.", "\u2022 (Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020.", "We exclude  this  significant  gain  because  gains  or  losses  on  investments  of  this  magnitude  do  not  typically  occur  in  the  normal  course  of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results.", "The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. \u2022 Transitional  tax  benefit,  net related  to  the  Tax  Cuts  and  Jobs  Act  is  excluded  because  it  results  from  the  one-time  impact  of  a  very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial  performance.  The  transitional  tax  benefit  includes  the  initial  estimate  and  subsequent  adjustments  for  the  re-measurement  of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.", "calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting  from  our  GAAP  net  loss  for  the  period.  Fiscal  2020,  non-GAAP  diluted  EPS  is  calculated  using  a  weighted  average  of  295  million  common  shares,  which includes potentially dilutive shares.", "Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation.", "This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\u201cCARES\u201d) Act.", "The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-", "The sum of the components and certain computations may reflect rounding adjustments.", "We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.", "During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).", "We are exposed to cash flow and earnings fluctuations as a result of certain market risks.", "By the  nature  of  our  global operations,  we are exposed to  cash flow and  earnings  fluctuations  resulting  from  foreign  exchange  rate variation.  These  exposures  are  transactional  and  translational  in nature.", "The following foreign currencies represent the principal drivers of  our  foreign  exchange  exposure:  Canadian  dollar,  euro,  Thai  baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.", "The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.", "Transactional Exposure Transactional  exposure  arises  from  the  purchase  and  sale  of  goods and  services  in  currencies  other  than  our  functional  currency  or  the functional currency of our subsidiaries.", "At the end of each fiscal year we perform sensitivity analyses on our", "We are exposed to changes in interest rates primarily as a result of our borrowing  and  investing  activities  to  maintain  liquidity  and  fund operations.  The  nature  and  amount  of  our  long-term  and  short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors.", "Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management.", "We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.", "As  part  of  our  risk  management  program,  we  perform  an  annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming  fiscal  year.  This  analysis  assumes  a  hypothetical  50  basis point change in interest rates.", "These analyses include the estimated impact of our hedging program, which is  designed  to  mitigate  transactional  exposure.  Applying  a  VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.", "Translational Exposure We have exposure related to the translation of financial statements of our  foreign  operations  into  U.S.  dollars,  our  functional  currency.", "Applying  a  VAR  methodology  to  our  translational  exposure,  the potential  maximum  loss  in  earnings  for  the  upcoming  fiscal  year  is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.", "We  are  also  exposed  to  market  risk  from  changes  in  interest  rates related  to  our  cash  and  cash  equivalents,  which  includes  marketable securities  that  are  carried  at  fair  value  in  the  consolidated  balance sheets.", "The fair value of our cash and cash equivalents is subject to change  primarily  as  a  result  of  changes  in  market  interest  rates  and investment  risk  related  to  the  issuers'  credit  worthiness.  At  June  30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.", "At June 30, 2020, we had hedged a portion of these direct commodity exposures  (see Note  10 of  the  \u201cNotes  to  Consolidated  Financial Statements\u201d  for  further  discussion).  There  were  no  outstanding commodity contracts in our hedging program at June 30, 2021.", "Our  forecasted  direct  commodity  exposures  for  the  upcoming  fiscal year  is  $449  million.  The  potential  gain/loss  given  a  hypothetical  10 percent  fluctuation  in  commodity  prices,  assuming  pricing  collectively shifts  in  the  same  direction  and  we  are  unable  to  change  customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021.", "The hypothetical offsetting impact of hedges in both periods was minimal.", "Margin  from  our  generic  pharmaceutical  program  includes  price discounts and rebates from manufacturers and may in limited instances include  price  appreciation.  Our  earnings  on  generic  pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.", "pharmaceutical  manufacturers  is  derived  from  compensation  we receive  for  providing  a  range  of  distribution  and  related  services  to manufacturers.  Our  compensation  typically  is  a  percentage  of  the wholesale  acquisition  cost  that  is  set  by  manufacturers.  In  addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.", "On  August  2,  2021,  we  completed  the  divestiture  of  our  Cordis business  to  Hellman  &  Freidman  (\"H&F\")  for  net  proceeds  of  $927 million in cash, subject to customary purchase price adjustments.", "In  August  2018,  we  completed  the  sale  of  our  equity  interest  in naviHealth,  Inc.  to  investor  entities  controlled  by  Clayton,  Dubilier  & Rice,  LLC  (\"CD&R\")  for  proceeds  of  $737  million  (after  adjusting  for certain  fees  and  expenses)  and  a  noncontrolling  equity  interest  in  a partnership  that  owned  naviHealth.  In  May  2020,  we  sold  the remainder of our equity interest in naviHealth.", "We had acquired our equity interest in naviHealth through a series of transactions  beginning  in  fiscal  2016,  when  we  acquired  a  majority equity interest.", "We  also  monitor  pay  equity.  We  define  pay  equity  as  equal  pay  for people  of  all  gender  identities  and  ethnicities  who  are  performing substantially  similar  work.  We  have  a  pay  equity  committee,  which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party,  to review  and help inform  our salary and compensation practices.", "Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.", "We  believe  that  we  have  taken  all  necessary  steps  to  protect  our proprietary rights, but no assurance can be given that we will be able to successfully  enforce  or  protect  our  rights  in  the  event  that  they  are infringed upon by a third party.", "Depending upon the specific  business,  we  may  be  subject  to  regulation  by  government entities including: \u2022 the U.S.", "The  Proposed  Settlement  Agreement,  as  described  in  the  Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of  the  Notes  to  Consolidated  Financial  Statements,  if  it  becomes effective,  also  includes  injunctive  relief  terms  related  to  settling distributors'  controlled  substance  anti-diversion  programs,  including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due  diligence  for  new  and  existing  customers;  (4)  ordering  limits  for certain products; and (5) suspicious order monitoring.", "We  also  collect,  handle,  and  maintain  other  sensitive  personal  and financial information.", "Within the U.S., these activities are regulated by certain  federal  and  state  laws.  For  example,  the  new  California Consumer  Privacy  Act  became  effective  in  January  2020  and  grants specified  rights  to  consumers  over  the  use  of  their  personal information,  including  increased  transparency.  Other  states  have adopted or are considering adopting similar or different comprehensive privacy  laws.  Internationally,  we  are  also  subject  to  privacy  and  data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information  Protection  and  Electronic  Documents  Act  (PIPEDA)  and Japan's Act on the Protection of Personal Information (APPI), among many others.", "Government Healthcare Programs We are subject to U.S. federal healthcare fraud and abuse laws.", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.  These  businesses  are  subject  to  accreditation  and  quality standards  and  other  rules  and  regulations,  including  applicable reporting,  billing,  payment  and  record-keeping  requirements.  Other businesses  within  each  segment  manufacture  pharmaceutical  or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid  and  other  federal  and  state  healthcare  programs.  For example,  the  United  States  Attorney\u2019s  Office  for  the  District  of Massachusetts  has  been  conducting  an  investigation  related  to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions.", "Our U.S. federal and state government contracts are subject to specific procurement  requirements.  Failure  to  comply  with  applicable  rules  or regulations  or  with  contractual  or  other  requirements  may  result  in monetary damages and criminal or civil penalties as well as termination of  our  government  contracts  or  our  suspension  or  debarment  from government contract work.", "Antitrust Laws The  U.S.  federal  government,  most  U.S.  states  and  many  foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive.  Violations  of  these  laws  can  result  in  various sanctions,  including  criminal  and  civil  penalties.  Private  plaintiffs  also could  bring  civil  lawsuits  against  us  in  the  United  States  for  alleged antitrust law violations, including claims for treble damages.", "Similarly,  we  are  subject  to  U.S.  and  foreign  laws  concerning  the conduct  of  our foreign  operations,  including the U.S.  Foreign Corrupt Practices Act, the U.K.", "For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that  our  internal  controls  were  not  sufficient  to  detect  improper payments  made  by  employees  of  our  former  China  distribution business.", "Our  customer  return  policies  generally  require  that  the  product  be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  product  for  credit  that  can  be  added  back  to inventory and resold at full value, or that can be returned to vendors for credit.", "The  risks  described  below  could  materially  and  adversely  affect  our results of operations, financial condition, liquidity or cash flows.", "Additionally, pricing actions have mitigated the impact of the increased costs  to  manufacture  and  source  PPE,  as  a  result  of  the  decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.", "Legal, Regulatory & Compliance Risks The public health crisis involving the abuse of prescription opioid pain  medication  and  our  efforts  to  resolve  related  claims  could have  additional  or  unexpected  material  negative  effects  on  our business.", "Our  Pharmaceutical  segment  distributes  prescription  opioid  pain medications.  In  recent  years,  the  abuse  of  prescription  opioid  pain medication has become a public health crisis.", "It is possible that we may fail to reach a final settlement.", "a press release stating that Washington will not agree to the Proposed Settlement  Agreement.  These  public  announcements  are  not  binding and  there  is  no  assurance  that  any  state  that  has  made  a  public announcement of support for the Proposed Settlement Agreement will ultimately  execute  the  Proposed  Settlement  Agreement.  It  is  also possible  that,  even  if  the  Proposed  Settlement  Agreement  becomes effective,  we could have trials for lawsuits brought by other states or subdivisions as well.", "West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.", "In  addition  to  the  claims  addressed  by  the  Proposed  Settlement Agreement,  we  are  also  being  sued  by  private  plaintiffs,  such  as unions,  other  health  and  welfare  funds,  hospital  systems,  other healthcare  providers  and  individuals  alleging  personal  injury  for  the same  activities  and  could  be  named  as  a  defendant  in  additional lawsuits.", "We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled substances.", "The  defense  and  resolution  of  current  and  future  lawsuits  and investigations  are  subject  to  uncertainty  and  could  have  a  material adverse  effect  on  our  results  of  operations,  financial  condition,  cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond  the  amounts  accrued.  In  addition,  they  could  have  adverse reputational or operational effects on our business.", "Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict.", "For example, several states have  now  adopted  or  proposed  taxes  or  other  fees  on  the  sale  of opioids.  These  laws  and  proposals  vary  in  the  tax  amounts  imposed and  the  means  of  calculation.  Liabilities  for  taxes  or  assessments under any such laws could have an adverse impact on our results of operations  unless  we  are  able  to  mitigate  them  through  operational changes or commercial arrangements where permitted.", "To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from,  and  to  comply  with  operating  and  security  standards  of, numerous  governmental  bodies.  For  example,  as  a  wholesale distributor  of  controlled  substances,  we  must  hold  valid  DEA registrations  and  state-level  licenses,  meet  various  security  and operating standards, and comply with the CSA.", "Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.", "We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information.", "Regulations currently in place continue to evolve, and  new  laws  in  this  area  could  further  restrict  our  ability  to  collect, handle and maintain personal or patient information, or could require us to  incur  additional  compliance  costs,  either  of  which  could  have  an adverse impact on our results of operations.", "Violations of federal, state or foreign laws concerning privacy and data protection could subject us to  civil  or  criminal  penalties,  breach  of  contract  claims,  costs  for remediation and harm to our reputation.", "We are required to comply with laws relating to healthcare fraud and abuse.  The  requirements  of  these  laws  are  complex  and  subject  to varying  interpretations.  From  time  to  time,  regulatory  authorities investigate our policies or practices, and may challenge them.", "We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act  on  behalf  of  federal  or  state  governments),  which  could  result  in civil or criminal sanctions, including the loss of licenses or the ability to participate  in  Medicare,  Medicaid  and  other  federal  and  state healthcare  programs  or  other  remedial  measures.  For  example,  the United  States  Attorney\u2019s  Office  for  the  District  of  Massachusetts  and the  Department  of  Health  and  Human  Services,  Officer  of  Inspector General  have  been  conducting  an  investigation  related  to  discounts and rebates offered or provided to certain Specialty", "Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such  as  state  Medicaid  programs  and  the  federal  340B  drug  pricing program.", "In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed  through,  or  are  otherwise  governed  by,  federal  or  state healthcare  programs.  Failure  to  comply  with  applicable  eligibility requirements, standards and regulations could result in civil or criminal sanctions,  including  the  loss  of  our  ability  to  participate  in  Medicare, Medicaid and other federal and state healthcare programs.", "Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts  or  our  suspension  or  debarment  from  government  contract work.", "If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal  sanctions.  For  example,  in  February  2020,  we  paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper  payments  made  by  employees  of  our  former  China distribution business.", "We could be subject to adverse changes in the tax laws or challenges to our tax positions.", "As a result, we are subject to the tax laws of many jurisdictions.", "From time to time, proposals are made in the United States and other jurisdictions  in  which  we  operate  that  could  adversely  affect  our  tax positions, effective tax rate or tax payments.", "initiatives  that  may  impact  us  include  possible  increases  in  U.S.  or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation  at  the  U.S.  state  level  on  the  basis  of  gross  revenues, recommendations  of  the  recently  completed  base  erosion  and  profit shifting  project  undertaken  by  the  Organization  for  Economic Cooperation  and  Development  and  the  European  Commission\u2019s investigation into illegal state aid.", "Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid.", "We have made reasonable estimates and  recorded  amounts  based  on  management's  judgment  and  our current understanding of the Tax Act; however, these estimates require significant judgment.", "In  fiscal  year  2021,  our  provision  for  income  taxes  reflects  a  $424 million benefit from the tax benefits of a net operating loss carryback under  the  CARES  Act.  Also  as  a  result  of  this  net  operating  loss carryback, we have filed for a U.S. federal income tax refund of $974 million.  In  connection  with  this  net  operating  loss  carryback,  certain industry  participants,  including  us,  received  a  letter  from  the  U.S.", "House  of  Representatives\u2019  Committee  on  Oversight  and  Reform questioning, among other things, our plans to take tax deductions for opioid-related  losses,  including  our  use  of  the  net  operating  loss carryback provisions under the CARES Act and deductibility under the Tax Act.", "Additionally, legislation has been  proposed  that  would  retroactively  repeal  the  net  operating  loss carryback  provision  of  the  CARES  Act.  If  these  initiatives  are successful, our effective tax rate could be adversely impacted.", "We file income tax returns in the U.S. federal jurisdiction, various U.S. state  jurisdictions  and  various  foreign  jurisdictions.  With  few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "Tax laws are complex and subject to varying interpretations.", "Tax authorities have challenged some of our tax  positions  for  the  periods  from  2011  to  2014.  During  fiscal  year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years.", "This resolution has resulted in an adjustment to our provision for income taxes.", "Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.", "Changes to the U.S. healthcare environment may not be favorable to us.", "Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by  healthcare  insurance  companies  to  further  limit  payments  for products  and  services  or  changes  in  legislation  or  regulations governing  prescription  pharmaceutical  pricing,  healthcare  services  or mandated  benefits.  These  possible  changes,  and  the  uncertainty surrounding these possible changes, may adversely affect us.", "Legal  proceedings  could  adversely  impact  our  cash  flows  or results of operations.", "Litigation  is  inherently  unpredictable  and  the  unfavorable  outcome  of legal  proceedings  could  adversely  affect  our  results  of  operations  or financial condition.", "In  addition,  product  liability  insurance  for  these  types  of  claims  is becoming more limited and may not be available to us at amounts that we  historically  have  obtained  or  that  we  would  like  to  obtain.  It  is possible  that  a  settlement  of  or  judgment  for  a  product  liability  claim may  not  be  covered  by  insurance  or  exceed  available  insurance recoveries.", "If this happens, and if any such settlement or judgment is in excess", "of any prior accruals, our results of operations and financial condition could be adversely affected.", "We also operate in an industry characterized by extensive intellectual property  litigation.  Patent  litigation  can  result  in  significant  damage awards and injunctions that could prevent the manufacture and sale of affected  products  or  force  us  to  make  royalty  payments  in  order  to continue selling the affected products.", "In  addition,  insurance  for  losses  arising  from  cyber-attacks  or  other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain.", "It is possible that we could incur losses that may not be covered  by  insurance  or  that  would  exceed  available  insurance recoveries.  If  this  happens,  our  results  of  operations  and  financial condition could be adversely affected.", "Our sales and credit concentration is significant.", "CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021.", "If CVS  terminates  the  agreements  due  to  an  alleged  default  by  us, defaults in payment or significantly reduces its purchases from us, our results  of  operations  and  financial  condition  could  be  adversely affected.", "We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis- synergies than expected, which could have a negative impact on our results of operations.", "Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from  the  acquisition;  our  management\u2019s  attention  may  be  diverted  to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill  or  intangible  assets;  we  may  face  difficulties  or  delays establishing,  integrating  or  combining  operations  and  systems, including manufacturing facilities; we may assume liabilities related to legal  proceedings  involving  the  acquired  business;  we  may  face challenges  retaining  the  customers  of  the  acquired  business;  or  we may  encounter  unforeseen  internal  control,  regulatory  or  compliance issues.", "Our goodwill may be impaired, which would require us to record a significant  charge  to  earnings  in  accordance  with  generally accepted accounting principles.", "GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist.", "For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent.", "Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit.", "For example, if we were to increase the discount rate by a hypothetical 0.5  percent,  the  carrying  value  of  our  Medical  Unit  would  have exceeded the fair value by approximately one percent in fiscal 2021.", "It  is  also  possible  that  we  may  record  significant  charges  related  to other reporting units.", "With respect to branded pharmaceutical products, compensation under our contractual  arrangements  with manufacturers  for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition  cost  set  by  the  manufacturer.  Sales  prices  of  branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.", "Also,  almost  all  of  our  distribution  services  agreements  with  branded pharmaceutical  manufacturers  provide  that  we  receive  fees  from  the manufacturers  to  compensate  us  for  services  we  provide  them.", "However,  under  certain  agreements,  branded  pharmaceutical  price appreciation, which is determined by the manufacturers also serves as a  part  of  our  compensation.  In  recent  years,  manufacturers  have increased  prices  less  than  in  prior  years.  If  manufacturers,  in  the aggregate,  change  their  historical  approach  to  setting  and  increasing wholesale  acquisition  cost,  decide  to  reduce  prices,  not  to  increase prices  or  to  implement  only  small  increases  and  we  are  unable  to negotiate  alternative  ways  to  be  compensated  by  manufacturers  or customers  for  the  value  of  our  services,  our  margins  could  be adversely affected.", "Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.", "Changes or uncertainty in U.S. or international trade policies  or  tariffs  could  impact  our  global  operations,  as  well  as  our customers and suppliers.", "In  addition,  we  conduct  our  business  in  U.S.  dollars  and  various functional  currencies  of  our  foreign  subsidiaries.  Changes  in  foreign currency  exchange  rates  could  adversely  affect  our  financial  results, which  are  reported  in  U.S.  dollars.  We  may  not  be  able  to  hedge  to protect  us  against  these  exposures,  and  any  hedges  may  not successfully mitigate these exposures.", "District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation.", "Our common shares are listed on the New York Stock Exchange under the symbol \u201cCAH.\u201d At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.", "We anticipate that we will continue to pay quarterly cash dividends in the future.", "The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.", "As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.", "Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.", "Management\u2019s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange  Act.  Our  internal  control  system  is  designed  to  provide  reasonable  assurance  regarding  the  reliability  of  financial  reporting  and  the preparation  of  financial  statements  for  external  purposes  in  accordance  with  generally  accepted  accounting  principles.  Because  of  its  inherent limitations, internal control  over financial reporting may  not prevent or detect misstatements.  Also, controls deemed effective  now may become inadequate  in  the  future  because  of  changes  in  conditions,  or  because  compliance  with  policies  or  procedures  has  deteriorated  or  been circumvented.", "Based on management\u2019s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.", "Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting.", "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.", "If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audit in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.", "Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.", "We believe that our audit provides a reasonable basis for our opinion.", "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.", "We  also  have  audited,  in  accordance  with  the  standards  of  the  Public  Company  Accounting  Oversight  Board  (United  States)  (PCAOB),  the Company's internal  control  over  financial reporting  as  of  June  30,  2021,  based  on  criteria  established in  Internal  Control-Integrated  Framework issued  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway  Commission  (2013  framework)  and  our  report  dated  August  16,  2021 expressed an unqualified opinion thereon.", "Our responsibility  is to express an opinion on the Company\u2019s financial statements based on our audits.", "We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.", "We conducted our audits in accordance with the standards of the PCAOB.", "Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.", "Our audits included performing  procedures  to  assess  the  risks  of  material  misstatement  of  the  financial  statements,  whether  due  to  error  or  fraud,  and  performing procedures that respond to those risks.", "Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.", "We believe that our audits provide a reasonable basis for our opinion.", "Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.", "The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.", "To test the estimated fair value of the Company\u2019s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy.", "We assessed the historical accuracy of management\u2019s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions.", "The Company believes there is a range of estimated losses with respect to these matters.", "Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range.", "Auditing management\u2019s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.", "For example, we tested controls over management\u2019s review of the model used  to  estimate  the  product  liability  reserve  amount  and  the  significant  assumptions  as  described  above  used  within  the model.", "To test management\u2019s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel,  and  we  discussed  with  internal  and  external  legal  counsel  of  the  plaintiffs\u2019  claims.  Among  other  procedures  we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate.", "In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve.", "We have also assessed the adequacy of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "Uncertain tax positions may arise as tax laws are subject to interpretation.", "Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company\u2019s process to assess the technical merits of its uncertain tax positions, including the Company\u2019s assessment as to whether a tax position is more likely than not to be sustained and management\u2019s process to measure the benefit of its tax positions.", "We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company\u2019s tax positions.", "Depending on the nature of the specific tax position and, where applicable, developments with the relevant  tax  authorities  relating  thereto,  our  procedures  included  obtaining  and  examining  the  Company\u2019s  analysis.  For example,  we  evaluated  the  underlying  facts  upon  which  the  tax  positions  are  based,  and,  where  applicable,  obtained  the Company\u2019s correspondence with local tax authorities.", "We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company\u2019s accounting for its uncertain tax positions.", "We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company\u2019s  positions.  We  analyzed  the  Company\u2019s  assumptions  and  data  used  to  evaluate  the  appropriateness  of  the Company\u2019s measurement of tax benefits.", "We have also evaluated the Company\u2019s income tax disclosures in relation to these matters.  Opioid Lawsuits", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency.", "For example, we tested controls over management\u2019s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts.", "To test the Company\u2019s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures,  we  read  the  Proposed  Settlement  Agreement,  requested  and  received  internal  and  external  legal  counsel confirmation  letters,  met  with  internal  counsel  to  discuss  the  status  of  the  proceedings  and  negotiations  of  the  Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management\u2019s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable.", "We also assessed the adequacy and the sufficiency of the Company\u2019s disclosures included in Note 7 in relation to these matters.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "The accompanying notes are an integral part of these consolidated statements.", "Basis of Presentation Our  consolidated  financial  statements  include  the  accounts  of  all majority-owned  or  controlled  subsidiaries,  and  all  significant", "Use of Estimates Our consolidated financial statements are prepared in accordance with accounting  principles  generally  accepted  in  the  United  States (\u201cGAAP\u201d).", "The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect  the  amounts  reported  in  the  consolidated  financial  statements and accompanying notes.", "Cash Equivalents We  consider  liquid  investments  purchased  with  an  initial  maturity  of three months or less to be cash equivalents.", "The carrying value of cash equivalents approximates fair value.", "In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account  is  considered  past  due.  We  regularly  monitor  past  due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer  credit  ratings  or  bankruptcies,  and  reasonable  and supportable  forecasts  to  develop  our  allowance  for  credit  losses.  We review  these  factors  quarterly  to  determine  if  any  adjustments  are needed  to  the  allowance.  We  write  off  any  amounts  deemed uncollectible against the established allowance for doubtful accounts.", "We  provide  financing  to  various  customers.  Such  financing", "We  estimate  an  allowance  for  these  financing  receivables  based  on historical collection rates and the credit worthiness of the customer.", "We write  off  any  amounts  deemed  uncollectible  against  the  established allowance for doubtful accounts.", "Concentrations of Credit Risk We maintain cash depository accounts with major banks, and we invest in  high  quality,  short-term  liquid  instruments,  and  in  marketable securities.  Our  short-term  liquid  instruments  mature  within  three months and we have not historically incurred any related losses.", "Our trade receivables and finance notes and related accrued interest are  exposed  to  a  concentration  of  credit  risk  with  certain  large customers  and  with  customers  in  the  retail  and  healthcare  sectors.", "With respect to customers in the retail and healthcare sectors, such credit risk is limited due  to  supporting  collateral  and  the  diversity  of  the  customer  base, including  its  wide  geographic  dispersion.  We  perform  regular  credit evaluations  of  our  customers\u2019  financial  conditions  and  maintain reserves  for  losses  through  the  established  allowance  for  doubtful accounts.", "Historically, such losses have been within our expectations.", "Major Customers CVS Health Corporation (\"CVS\") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables.", "Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively.  Our  trade  receivable  balances  are  with  individual members  of  the  GPO,  and  therefore  no  significant  concentration  of credit risk exists with these types of arrangements.", "We do not record inventories in excess of replacement cost.", "As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.", "As selling prices and customer demand have decreased compared to the peak  of  COVID-19,  we  recorded  a  reserve  of  $197  million,  primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.", "Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which  are  depreciated  over  the  terms  of  their  respective  leases.  We generally use the following range of useful lives for our property and equipment  categories:  buildings  and  improvements\u20143  to  39  years; machinery and equipment\u20143 to 20 years; and furniture and fixtures\u20143 to  7  years.  We  recorded  depreciation  and  amortization  expense  of $377 million,  $405 million and $455 million for  fiscal  2021,  2020 and 2019, respectively.", "Interest  on  long-term  projects  is  capitalized  using  a  rate  that approximates the weighted-average interest rate on long-term", "Purchased  goodwill  is  tested  for  impairment  at  least  annually.", "We have elected to bypass the qualitative  assessment  for our annual goodwill impairment  test  in the current  year.  The  quantitative  goodwill  impairment  test  involves  a comparison  of  the  estimated  fair  value  of  the  reporting  unit  to  the respective carrying amount.", "Our determination of estimated fair value of the reporting units  is  based  on  a  combination  of  the  income-based  and  market- based  approaches.  Under  the  income-based  approach,  we  use  a discounted  cash  flow  model  in  which  cash  flows  anticipated  over several  future  periods,  plus  a  terminal  value  at  the  end  of  that  time horizon, are discounted to their present value using an appropriate risk- adjusted rate of return.", "We use our internal forecasts to estimate future cash  flows,  which  we  believe  are  consistent  with  those  of  a  market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit.", "Actual  results  may  differ  materially  from  those  used  in  our  forecasts.", "We  use  discount  rates  that  are  commensurate  with  the  risks  and uncertainty  inherent  in  the  respective  reporting  units  and  in  our internally-developed forecasts.", "Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent.", "determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.", "To further confirm fair value, we compare the aggregate fair value of our reporting units to our total  market  capitalization.  Estimating  the  fair  value  of  reporting  units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results.", "The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.", "We performed annual impairment testing in fiscal 2021, 2020 and 2019 and  concluded  that  there  were  no  impairments  of  goodwill  as  the estimated fair value of each reporting unit exceeded its carrying value.", "The impairment test for indefinite-lived intangibles other than goodwill involves  first  assessing  qualitative  factors  to  determine  if  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is  less  than  its  carrying  amount.  If  so,  then  a  quantitative  test  is performed  to  compare  the  estimated  fair  value  of  the  indefinite-lived intangible  asset  to  the  respective  asset's  carrying  amount.  Our qualitative  evaluation  requires  the  use  of  estimates  and  significant judgments and considers the weight of evidence and significance of all identified  events  and  circumstances  and  most  relevant  drivers  of  fair value,  both  positive  and  negative,  in  determining  whether  it  is  more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.", "We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying  amounts  may  not  be  recoverable.  Determining  whether  an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group.", "Actual results may differ materially from those used in our forecasts.", "Assets Held for Sale We classify assets and liabilities (the \u201cdisposal group\u201d) as held for sale when management commits to a plan to sell the disposal group in its present  condition  and  at  a  price  that  is  reasonable  in  relation  to  its current  fair  value.  We  also  consider  whether  an  active  program  to locate a buyer has been initiated and if it is probable that the sale will occur  within  one  year  without  significant  changes  to  the  plan  to  sell.", "Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.", "On  March  12,  2021,  we  announced  that  we  signed  a  definitive agreement  to  sell  our  Cordis  business  to  Hellman  &  Friedman  for proceeds of $927 million in cash, subject to customary purchase price adjustments,  and  we  retained  certain  working  capital  accounts  and certain liabilities, including product liability for", "For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer.", "For investments in which we can exercise significant influence but do not control, we use the equity method of accounting.", "Our  share  of  the  earnings  and  losses  are  recorded  in  other (income)/expense,  net  in  the  consolidated  statements  of", "earnings/(loss).  We  monitor  our  investments  for  impairment  by considering  factors  such  as  the  operating  performance  of  the investment and current economic and market conditions.", "Vendor Reserves In  the  ordinary  course  of  business,  our  vendors  may  dispute deductions  taken  against  payments  otherwise  due  to  them  or  assert other  disputes.  These  disputes  are  researched  and  resolved  based upon the findings of the research performed.", "We have established various levels of reserves based on the type  of  claim  and  status  of  review.  Though  the  claim  types  are relatively  consistent,  we  periodically  refine  our  methodology  by updating  the  reserve  estimate  percentages  to  reflect  actual  historical experience.  The  ultimate  outcome  of  certain  claims  may  be  different than our original estimate and may require an adjustment.", "Distribution Services Agreement and Other Vendor Fees Our  Pharmaceutical  segment  recognizes  fees  received  from", "distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors\u2019 inventory when those  fees  have been earned and we are entitled  to payment.  Since the  benefit  provided  to  a  vendor  is  related  to  the  purchase  and distribution  of  the  vendor\u2019s  inventory,  we  recognize  the  fees  as  a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.", "Loss Contingencies and Self-Insurance Loss Contingencies We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.", "In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate.", "In July  2021,  we announced that  we and two other  national distributors have negotiated a proposed settlement  agreement,  subject  to certain conditions  and  contingencies.  There  is  no  assurance  that  the contingencies to the proposed settlement agreement will be satisfied.", "To project  future  Cordis  IVC  claim  costs,  we  use  a  methodology  based largely  on  recent  experience,  including  claim  filing  rates,  estimated indemnity  severity  by  claim  type,  sales  data,  implant  and  injury  to report lag patterns and estimated defense costs.", "Self-Insurance We  also  self-insure  for  employee  healthcare,  general  liability,  certain product  liability  matters,  auto  liability,  property  and  workers' compensation.  Self-insurance  accruals  include  an  estimate  for expected settlements or pending claims, defense costs, administrative fees,  claim  adjustment  costs  and  an  estimate  for  claims  incurred  but not reported.", "Because  these  matters  are  inherently  unpredictable  and  unfavorable developments  or  resolutions  can  occur,  assessing  contingencies  and other  liabilities  is  highly  subjective  and  requires  judgments  about future  events.  We  regularly  review  contingencies  and  our  self- insurance  accruals  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ materially from these estimates.", "We  recognize  these  estimated  loss  contingencies,  income  from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).", "Guarantees In the ordinary course of business, we agree to indemnify certain other parties  under  acquisition  and  disposition  agreements,  customer agreements,  intellectual  property  licensing  agreements,  and  other agreements.", "Historically,  we have not, individually or in the aggregate, made", "In certain circumstances, we believe that existing insurance arrangements,  subject  to  the  general  deduction  and  exclusion provisions,  would  cover  portions  of  the  liability  that  may  arise  from these  indemnification  obligations.  In  addition,  we  believe  that  the likelihood  of  a  material  liability  being  triggered  under  these indemnification obligations is not probable.", "From time to time we enter into agreements that obligate us to make fixed  payments  upon  the  occurrence  of  certain  events.  Such obligations  primarily  relate  to  obligations  arising  under  acquisition transactions,  where  we  have  agreed  to  make  payments  based  upon the  achievement  of  certain  financial  performance  measures  by  the acquired  business.  Generally,  the  obligation  is  capped  at  an  explicit amount.", "Income Taxes We  account  for  income  taxes  using  the  asset  and  liability  method.", "Deferred  tax  assets  and  liabilities  are  measured  using  enacted  tax rates in the respective jurisdictions in which we operate.", "We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized.", "The  realizability  of  deferred  tax  assets  depends  on  our  ability  to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.", "We operate in a complex multinational tax environment and are subject to  tax  treaty  arrangements  and  transfer  pricing  guidelines  for intercompany  transactions  that  are  subject  to  interpretation.", "Uncertainty  in  a  tax  position  may  arise  as  tax  laws  are  subject  to interpretation.", "Tax  benefits  from  uncertain  tax  positions  are  recognized  when  it  is more  likely  than  not  that  the  position  will  be  sustained  upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes.", "The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement.", "For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.", "Noncontrolling Interests Noncontrolling  interests  represent  the  portion  of  net  earnings, comprehensive  income  and  net  assets  that  is  not  attributable  to Cardinal Health, Inc.", "Share-Based Compensation Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value  of  the  awards.  The  fair  value  of  restricted  share  units  and performance share units is determined by the grant date market price of our common shares.", "The fair value of stock options is determined on the  grant  date  using  a  lattice  valuation  model.  The  compensation expense  associated  with  nonvested  performance  share  units  is dependent on our periodic assessment of the probability of the targets being  achieved  and  our  estimate,  which  may  vary  over  time,  of  the number  of  shares  that  ultimately  will  be  issued.  The  compensation expense  recognized  for  share-based  awards  is  net  of  estimated forfeitures  and  is  recognized  ratably  over  the  service  period  of  the awards.", "Dividends We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.", "Revenue Recognition We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.", "We are generally the principal in a transaction, therefore our revenue is primarily  recorded  on  a  gross  basis.  When  we  are  a  principal  in  a transaction, we have determined that we control the ability to direct the use  of  the  product  or  service  prior  to  transfer  to  a  customer,  are primarily responsible for fulfilling the promise to provide the product or service  to  our  customer,  have  discretion  in  establishing  prices,  and ultimately control the transfer of the product or services provided to the customer.", "Our customer return policies generally require that the product be physically  returned,  subject  to  restocking  fees.  We  only  allow customers  to  return  products  for  credit  in  a  condition  suitable  to  be added  back  to  inventory  and  resold  at  full  value  (\u201cmerchantable product\u201d)  or  returned  to  vendors  for  credit.  Product  returns  are generally consistent throughout the year and typically are not specific to any particular product or customer.", "We accrue for estimated sales returns and allowances at the time of sale  based  upon  historical  customer  return  trends,  margin  rates  and processing  costs.  Our  accrual  for  sales  returns  is  reflected  as  a reduction of revenue and cost of products sold for the sales price and cost,  respectively.  At  June  30,  2021  and  2020,  the  accrual  for estimated  sales  returns  and  allowances  was  $689  million  and  $495 million,  respectively,  which  is  reflected  in  trade  receivables,  net  and inventories, net in the consolidated balance sheets.", "Third-Party Returns We generally do not accept non-merchantable pharmaceutical product returns  from  our  customers,  so  many  of  our  customers  return  non- merchantable  pharmaceutical  products  to  the  manufacturer  through third  parties.  Since  our  customers  generally  do  not  have  a  direct relationship  with  manufacturers,  our  vendors  pass  the  value  of  such returns to us (usually in the form of an accounts payable deduction).", "We,  in  turn,  pass  the  value  received  to  our  customer.  In  certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor.", "Although we believe we  have  satisfactory  protections,  we  could  be  subject  to  claims  from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict  with  our  contractual  terms  with  our  customers.  We  have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.", "Shipping and Handling Shipping and handling costs are primarily included in SG&A expenses in  our  consolidated  statements  of  earnings/(loss)  and  include  all delivery  expenses  as  well  as  all  costs  to  prepare  the  product  for shipment to the end customer.", "employee  severance  costs  that  are not  incurred  in connection  with a restructuring  activity.  See Note  3 for  additional  information  regarding our restructuring activities.", "Amortization and Other Acquisition-Related Costs We  classify  certain  costs  incurred  in  connection  with  acquisitions  as amortization  and  other  acquisition-related  costs  in  our  consolidated statements  of  earnings/(loss).  These  costs  consist  of  amortization  of acquisition-related  intangible  assets,  transaction  costs,  integration costs  and  changes  in  the  fair  value  of  contingent  consideration obligations.", "Integration costs relate to activities required to combine the operations  of  an  acquired  enterprise  into  our  operations  and,  in  the case of the Cordis and Patient Recovery businesses, to stand-up the systems  and  processes  needed  to  support  an  expanded  geographic footprint.  We  record  changes  in  the  fair  value  of  contingent consideration obligations relating to acquisitions as income or expense in  amortization  and  other  acquisition-related  costs.  See Note  4 for additional  information  regarding  amortization  of  acquisition-related intangible assets.", "Translation of Foreign Currencies Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency.", "Interest Rate, Currency and Commodity Risk All  derivative  instruments  are  recognized  at  fair  value  on  the consolidated  balance  sheets  and  all  changes  in  fair  value  are recognized in net earnings or shareholders\u2019 equity through AOCI, net of tax.", "For  contracts  that  qualify  for  hedge  accounting  treatment,  the  hedge contracts  must  be  effective  at  reducing  the  risk  associated  with  the exposure  being  hedged  and  must  be  designated  as  a  hedge  at  the inception of the contract.", "Any  contract  not  designated  as  a  hedge,  or  so  designated  but ineffective, is adjusted to fair value and recognized immediately in net earnings.", "See Note  10 for  additional  information  regarding  our  derivative instruments,  including  the  accounting  treatment  for  instruments designated  as  fair  value,  cash  flow,  net  investment  and  economic hedges.", "Fair Value Measurements Fair value is defined as the price that would be received upon selling an  asset  or  the  price  paid  to  transfer  a  liability  on  the  measurement date.", "We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit  losses.  We  review  these  factors  quarterly  to  determine  if  any adjustments are needed to the allowance.", "This guidance was effective beginning the  first  quarter  of  fiscal  2021 and did not  have  a material impact on our consolidated financial statements.", "Recently Issued Financial Accounting Standards Not Yet Adopted We  address  the  adoption  impacts  of  recently  issued  accounting standards by the FASB on the our consolidated financial statements as well  as  material  updates  to  previous  assessments,  if  any,  from  our fiscal 2020 Form 10-K.", "market activity and that are significant to the fair value of the assets and liabilities.", "standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. 2.", "Divestitures Cordis Assets Held for Sale On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in  cash,  subject  to  customary  purchase  price  adjustments,  and  we retained  certain  working  capital  accounts  and  certain  liabilities.  The transaction  closed  on  August  2,  2021  and  we  received  proceeds  of $927 million, net of cash transferred.", "Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale.", "In connection  with  the  divestiture,  we  allocated  $388  million  of  goodwill from  the  Medical  Unit  (within  our  Medical  Segment)  to  the  Cordis disposal  group  based  on  the  estimated  relative  fair  values  of  the business to be disposed of and the portion of the reporting unit that will be retained.", "We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.", "At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell.", "Accordingly, we recognized a $60 million pre-tax  write-down  on  the  disposal  group  in  impairments  and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statement  of earnings/(loss).  This  write-down  includes  a  $3  million  loss  related  to currency translation adjustments in accumulated other comprehensive loss.", "We recorded a net tax expense of $9 million associated with the impact  of  the write-down  and the required  tax adjustments  related  to held for sale accounting.", "naviHealth In August 2018, we sold our majority ownership interest in naviHealth, which  operated  within  our  Medical  segment  in  exchange  for  cash proceeds of $737 million (after adjusting for certain fees and expenses) and  a  noncontrolling  equity  interest  in  a  partnership  that  owned naviHealth.", "We also had certain call rights to reacquire naviHealth.", "As  a  result  of  this  divestiture,  during  the  fiscal  year  ended  June  30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss  on  disposal  of  assets  in  our  consolidated  statements  of earnings/(loss).  This  gain  included  our  initial  recognition  of  an  equity method  investment  for  $358  million  and  the  derecognition  of redeemable noncontrolling interests of $12 million.", "The fiscal 2019 tax expense  as  a  result  of  this  transaction  was  $130  million.  We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.", "In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth.", "We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth  in  our  consolidated  statements  of  earnings/(loss)  during fiscal year 2020.", "Our proportionate share of naviHealth\u2019s results, which was recorded in other  (income)/expense,  net  in  the  consolidated  statements  of earnings/(loss),  was  income  of  $2  million  and  a  loss  of  $10  million during fiscal 2020 and 2019, respectively.", "In connection with the divestiture of our Cordis business, during fiscal 2021  we  allocated  and  reclassified  $388  million  of  goodwill  from  the Medical Unit (within our Medical Segment) to the Cordis disposal group based  on  the  estimated  relative  fair  values  of  the  business  to  be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.", "We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of  the  asset.  Our  lease  agreements  generally  do  not  contain  any material residual value guarantees or material restrictive covenants.", "Beginning  July  1,  2019,  operating  lease  right-of-use  assets  and corresponding  operating  lease  liabilities  are  recognized  in  our consolidated balance sheets  at lease commencement  date based on the  present  value  of  lease  payments  over  the  lease  term.  Operating lease expense for operating lease assets is recognized on a straight- line basis over the lease term.", "As most of our leases do not provide an implicit  rate,  we  use  our  collateralized  incremental  borrowing  rate based on the information available at the lease commencement date in determining the present value of lease payments.", "We use the implicit rate if it is readily determinable.", "Our  lease  agreements  contain  lease  components  and  non-lease components.", "For all asset classes, we have elected to account for both of these components as a single lease component.", "We also, from time to  time,  sublease  portions  of  our  real  estate  property,  resulting  in sublease  income.  Sublease  income  and  the  related  assets  and  cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.", "We  also  have  elected  to  apply  a  practical  expedient  for  short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months.", "Short-term lease expense  recognized  in  fiscal  2021  and  2020  was  not  material.  In addition,  upon  adoption  of  the  new  lease  standard,  we  elected  the package  of  three  practical  expedients  permitted  under  the  transition guidance,  which  include  the  carry  forward  of  our  leases  without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.", "Our  leases  have  remaining  lease  terms  from  less  than  1  year  up  to approximately 21 years.", "Our lease terms may include options to extend or  terminate  the  lease  when  it  is  reasonably  certain  and  there  is  a significant economic incentive to exercise that option.", "Variable  lease  cost  primarily  includes  payments  for  property  taxes, maintenance  and insurance.  Our rental expense relating to operating leases was $153 million in fiscal 2019.", "Operating leases are included in other assets, other accrued liabilities, and  deferred  income  taxes  and  other  liabilities  in  our  consolidated balance sheet.", "Finance leases are included in property and equipment, net,  current  portion  of  long-term  obligations  and  other  short-term borrowings,  and  long-term  obligations,  less  current  portion  in  our consolidated balance sheet.", "(1) As  of  June  30,  2021,  we had  certain  leases  that  were  executed  but  did  not have control of the underlying assets; therefore, the lease liabilities and right- of-use assets are not recorded in the consolidated balance sheet. 6.  Long-Term  Obligations  and  Other  Short-Term Borrowings", "Long-Term Debt All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured  and  unsubordinated  indebtedness.  The  7.0%  Debentures represent  unsecured  obligations  of  Allegiance  Corporation  (a  wholly- owned subsidiary), which Cardinal Health, Inc. has guaranteed.", "None of  these  obligations  are  subject  to  a  sinking  fund  and  the  Allegiance obligations  are  not  redeemable  prior  to  maturity.  Interest  is  paid pursuant  to  the  terms  of  the  obligations.  These  notes  are  effectively subordinated  to  the  liabilities  of  our  subsidiaries,  including  trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.", "In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes  due  June  2022  at  a  redemption  price  equal  to  100%  of  the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.", "During  fiscal  2021,  we  also  early  repurchased  $40  million  of  the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022  with  available  cash.  In  connection  with  the  early  debt repurchases, we recorded a $1 million loss on early extinguishment of debt.", "During  fiscal  2020,  we  redeemed  $500  million  aggregate  principle amount  of  4.625%  Notes  due  December  2020  at  a  redemption  price equal to 100% of the principal amount and accrued but unpaid interest, plus  the  make-whole  premium  applicable  to  the  notes.  In  connection with  the  redemption,  we  recorded  a  $7  million  loss  on  early extinguishment  of  debt.  We  also  early  repurchased  $247  million  of the  2.616%  Notes  due  2022,  $11  million  of  the  3.2%  Notes  due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the  3.41%  Notes  due  2027,  $6  million  of  the  4.6%  Notes  due 2043,  $5  million  of  the  4.9%  Notes  due  2045,  and  $35  million  of the  4.368%  Notes  due  2047.  In  connection  with  the  early  debt repurchases, we recognized a $9 million loss on early extinguishment of debt.", "We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.", "During  fiscal  2019,  we  repurchased  $67  million  of  the  2.616%  Notes due  2022,  $1  million  of  the  3.2%  Notes  due  2022,  8  million  of  the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027  for  a  total  of  $100  million.  The  loss  on  early  extinguishment  of debt  in  connection  with  these  early  repurchases  was  immaterial.  We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.", "On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.", "If we undergo a change of control, as defined in the notes, and if the notes  receive  specified  ratings  below  investment  grade  by  each  of Standard  &  Poors  Ratings  Services,  Moody\u2019s  Investors  Services  and Fitch Ratings, any holder of the notes, excluding the debentures, can require  with  respect  to  the  notes  owned  by  such  holder,  or  we  can offer,  to  repurchase  the  notes  at  101%  of  the  principal  amount  plus accrued and unpaid interest.", "We also have a $1.0 billion committed receivables sales facility.", "In  September  2019,  we  renewed  our  committed  receivables  sales facility program through Cardinal Health Funding, LLC (\u201cCHF\u201d) through September  30,  2022.  CHF  was  organized  for  the  sole  purpose  of buying receivables and selling undivided interests in those receivables to third-party purchasers.", "Although consolidated with Cardinal Health, Inc.  in  accordance  with  GAAP,  CHF  is  a  separate  legal  entity  from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF.  CHF  is  designed  to  be  a  special  purpose,  bankruptcy-remote entity  whose  assets  are  available  solely  to  satisfy  the  claims  of  its creditors.", "Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75- to-1.  As  of  June  30,  2021,  we  were  in  compliance  with  this  financial covenant.", "At June 30, 2021 and 2020, we had no amounts outstanding under the revolving  credit  facility;  however,  availability  was  reduced  by outstanding  letters  of  credit  of  $1  million  at  both  June  30,  2021  and 2020.", "Under  our  committed  receivables  sales  facility  program,  we  had  a maximum amount outstanding of $200 million and an immaterial daily amount  outstanding  during  fiscal  2021.  We  had  no  amounts outstanding as of June 30, 2021 under the committed receivables sales facility  program;  however,  availability  was  reduced  by  outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.", "We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.", "We  also  maintain  other  short-term  credit  facilities  and  an  unsecured line  of  credit  that  allowed  for  borrowings  up  to  $6  million  at  both June 30, 2021 and 2020.", "In August 2021, we amended our agreement to extend the term through June 2029.", "We are required to make quarterly payments to CVS Health for the term of the arrangement.", "We  accrue  contingencies  if  it  is  probable  that  a  liability  has  been incurred  and  the  amount  can  be  estimated.  Because  of  the  Second Circuit  ruling,  we  recorded  an  aggregate  accrual  of  $41  million  for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.", "Legal Proceedings We  become  involved  from  time  to  time  in  disputes,  litigation  and regulatory matters.", "When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action.", "investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.", "We have been named from time to time in qui tam actions initiated by private third parties.", "These actions may remain under seal while the government makes this determination.", "If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.", "We  accrue  for  contingencies  related  to  disputes,  litigation  and regulatory matters if it is probable that a liability has been incurred and the  amount  of  the  loss  can  be  reasonably  estimated.  Because  these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires  judgments  about  future  events.  We  regularly  review contingencies  to  determine  whether  our  accruals  and  related disclosures are adequate.", "The amount of ultimate loss may differ from these estimates.", "We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.", "We  recognize  estimated  loss  contingencies  for  certain  litigation  and regulatory matters and income from favorable resolution of litigation in litigation  (recoveries)/charges  in  our  consolidated  statements  of earnings/(loss).", "Opioid Lawsuits and Investigations Pharmaceutical wholesale distributors, including us, have been named as  defendants  in  approximately  3,300  lawsuits  relating  to  the distribution of prescription opioid pain medications.", "In  addition,  25  state  attorneys  general  have  filed  lawsuits  against distributors,  including  us,  in  various  state  courts.  We  have  also received requests, civil investigative demands, subpoenas or requests for  information  from  additional  state  attorneys  general  offices  and governmental authorities.", "In July, 2021, we announced that we and two other national distributors have  negotiated  a  proposed  settlement  agreement  (the  \u201cProposed Settlement  Agreement\u201d)  and  settlement  process  that,  if  all  conditions are  satisfied,  would  result  in  the  settlement  of  the  vast  majority  of opioid  lawsuits  filed  by  state  and  local  governmental  entities.  West Virginia subdivisions and Native American tribes are not a part of this settlement  process  and  we  have  been  involved  in  separate negotiations  with  these  groups.  The  settlement  process  does  not contemplate  participation  by  any  non-governmental  or  non-political entities  or  individuals.  In  connection  with  the  negotiations  of  the Proposed  Settlement  Agreement,  we  and  the  two  other  national distributors entered into a settlement with the State of New York and its participating  subdivisions.  If  the  Proposed  Settlement  Agreement becomes  effective,  New  York  and  its  participating  subdivisions  will become a part of it.", "If  these conditions  are satisfied,  the Proposed Settlement  Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions.", "The  Proposed  Settlement  Agreement  also  includes  injunctive  relief terms related to settling distributors\u2019 controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and  training  of  the  personnel  operating  our  controlled  substances monitoring program; (3) due diligence for new and existing customers; (4)  ordering  limits  for  certain  products;  and  (5)  suspicious  order monitoring.", "In  total,  we  have  recorded  total  pre-tax  charges  of  $1.17  billion  and $5.63  billion in  litigation charges/(recoveries),  net  in  the  years  ended June 30, 2021 and 2020, respectively.  In total, we have $6.73 billion accrued  at  June  30,  2021,  of  which  $405  million  is  included  in  other accrued  liabilities  and  the  remainder  is  included  in  deferred  income taxes and other liabilities in the consolidated balance sheets.", "Because  loss  contingencies  are  inherently  unpredictable  and unfavorable developments or resolutions can occur, the assessment is highly  subjective  and  requires  judgments  about  future  events.  We regularly review these opioid litigation matters to determine whether our accrual is adequate.", "The amount of ultimate loss may differ materially from  this  accrual,  whether  as  a  result  of  settlement  discussions,  a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters.", "We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.", "A trial in one case  is  currently  scheduled  to  begin  in  October  2021.  We  are vigorously defending ourselves in these matters.", "Insurance Litigation We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above.", "In October  2020,  we  filed  a  complaint  for  declaratory  judgment  against National  Union  Fire  Insurance  Company  of  Pittsburgh,  PA  (\u201cNational Union\u201d)  seeking  a  declaration  that  National  Union  is  obligated  to reimburse us for defense costs incurred in connection with the lawsuits described  above.  In  January,  2021,  Swiss  Re  International  SE commenced  an  arbitration  in  London  seeking  a  determination  that  it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above.", "We have  not  recorded  a  receivable  for  any  recoveries  related  to  these insurance litigation matters as of June 30, 2021.", "Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with  investigations  being  conducted  by  the  U.S.  Attorney's  Office  for the  Eastern  District  of  New  York  and  the  Fraud  Section  of  the  U.S.", "We have also received civil requests for information  from  other  DOJ  offices.  We  believe  that  these investigations  concern  operation  of  our  anti-diversion  program,  our anti-diversion  policies  and  procedures,  and  distribution  of  certain controlled  substances.  We  are  cooperating  with  these  requests.  We are unable to predict the outcome of any of these investigations.", "These lawsuits seek a variety of remedies, including unspecified  monetary  damages.  In  July  2021,  we  entered  into  an agreement  to  settle  approximately  1,300  claims.  This  agreement  is subject  to  certain  contingencies.  We  continue  to  vigorously  defend ourselves  in  these  lawsuits  and  are  engaged  in  ongoing  resolution discussions with certain plaintiffs.", "At  June  30,  2021,  we  had  a  total  of  $524  million  net  of  estimated insurance recoveries, accrued for losses and legal defense costs, net of  expected  insurance  recoveries,  related  to  the  Cordis  IVC  filter lawsuits  in  the  consolidated  balance  sheets.  We  believe  there  is  a range of estimated losses with respect to these matters.", "Because no amount  within  the  range  is  a  better  estimate  than  any  other  amount within the range, we have accrued the minimum amount in the range.", "We  estimate  the  high  end  of  the  range  to  be  approximately $1.03  billion,  net  of  estimated  insurance  recoveries.  The  sale  of  the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.", "We are cooperating with this inquiry and cannot predict its outcome or duration.", "Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported  class  action  complaint  against  Cardinal  Health  and  certain current and former officers and employees in the United States District Court  for  the  Southern  District  of  Ohio  purportedly  on  behalf  of  all purchasers  of  our  common  shares  between  March  2015  and  May 2018.  In  June  2020,  the  court  appointed  1199  SEIU  Health  Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint  was  filed  in  September  2020.  The  amended  complaint alleges  that  the  defendants  violated  Sections  10(b)  and  20(a)  of  the Securities  and  Exchange  Act  of  1934  by  making  misrepresentations and  omissions  related  to  the  acquisition  integration  of  the  Cordis business  and  inventory  and  supply  chain  problems  within  the  Cordis business,  and  seeks  to  recover  unspecified  damages  and  equitable relief for the alleged misstatements and omissions.", "In November 2020, we filed a motion to dismiss the amended complaint.", "complaint  are  without  merit  and  intend  to  vigorously  defend  against them.", "In connection with these discussions,  we  recorded  $13  million  of  expense  within  litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during  the  fiscal  year  ended  June  30,  2021.  We  cannot  predict  the outcome  of  the  discussions  and  it  is  possible  that  we  may  incur additional  losses  or  agree  to  other  remedial  measures;  however,  we are  not  currently  able  to  estimate  a  range  of  reasonably  possible additional losses.", "Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In  December  2019,  pharmaceutical  distributors  including  us  were added  as  defendants  in  a  civil  class  action  lawsuit  filed  by  indirect purchasers of generic drugs, such as hospitals and retail pharmacies.", "We have filed a motion to  dismiss  the  complaints  and  we  intend  to  vigorously  defend ourselves.", "We have been  named  as  a  defendant  in  the  Sartan  MDL.  We  are  vigorously defending ourselves in this matter.", "Antitrust Litigation Proceeds We  received  and  recognized  income  resulting  from  settlements  of lawsuits in which we were a class member or plaintiff of $112 million, $16  million  and  $94  million  during  fiscal  2021,  2020,  and  2019, respectively.", "Tax Effects of Self-Insurance Pre-Tax Loss During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance  pre-tax  loss  in  its  fiscal  2020  statutory  financial statements primarily related to opioid litigation.", "This self-insurance pre- tax  loss,  which  did  not  impact  our  pre-tax  consolidated  results,  was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes.", "The net operating  loss  was  carried  back  and  applied  to  adjust  our  taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (\"CARES\") Act enacted by the United States Congress in March 2020.", "Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect  the  difference  between  the  federal  statutory  income  tax  rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.", "We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021.", "We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could  change.  The  actual  amount  of  the  tax  benefit  may  differ materially from these estimates.", "Tax Effects of Opioid Litigation Charges In connection with the $1.17 billion and $5.63 billion pre-tax charges for the  opioid  litigation,  during  fiscal  2021  and  2020,  we  recorded  a  tax benefit of $228 million and $488 million, respectively.", "Our tax benefits are estimates,  which reflect  our current  assessment  of  the estimated future deductibility of the amount that may be paid under the accrual taken  in  connection  with  the  opioid  litigation  and  are  net  of unrecognized  tax  benefits  of  $219  million  and  $469  million, respectively.", "We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however,  these  estimates  require  significant  judgment  since  the  U.S. tax law governing deductibility was changed by the U.S.", "Effective Tax Rate The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:", "benefit,  fiscal  2020  is  pretax  loss  with  tax  benefit,  and  fiscal  2019  is  pretax income with tax expense.", "Our effective tax rate has benefits from negotiated lower than statutory tax  rates  in  select  foreign  jurisdictions  which  individually  are  not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.", "As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment  needs.  The  computation  of  tax  required  if  those  earnings are  repatriated  is  not  practicable.  For  amounts  not  considered indefinitely  reinvested,  we  have  recorded  an  immaterial  amount  of income tax expense in our financial statements in fiscal 2021.", "At June 30, 2021 we had gross federal, state and international loss and credit  carryforwards  of  $272  million,  $3.9  billion  and  $2.3  billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million.", "Substantially all of these carryforwards are available for at  least  three  years.  Approximately  $477  million  of  the  valuation allowance  at  June  30,  2021  applies  to  certain  federal,  state  and international  loss  carryforwards  that,  in  our  opinion,  are  more  likely than not to expire unutilized.", "However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.", "Unrecognized Tax Benefits We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively.", "Recognition of these tax benefits would not  affect  our effective  tax  rate.  We  include the full  amount  of unrecognized tax benefits in deferred income taxes and other liabilities in  the  consolidated  balance  sheets.  The  following  table  presents  a reconciliation of the beginning and ending amounts of unrecognized tax benefits:", "reassessment of existing unrecognized tax benefits or the expiration of statutes  of  limitations.  We  estimate  that  the  range  of  the  possible change in unrecognized tax benefits within the next 12 months is a net decrease  of  $0  million  to  $20  million,  exclusive  of  penalties  and interest.", "We recognize accrued interest  and penalties related to unrecognized tax benefits in the provision for income taxes.", "At June 30, 2021, 2020 and  2019,  we  had  $49  million,  $146  million  and  $122  million, respectively, accrued for the payment of interest and penalties.", "As a result of our IRS audit settlements and carryback claim,  an  immaterial  amount  of  interest  was  recorded  in  fiscal  2021.", "During fiscal 2020 and 2019, we recognized $16 million and $8 million of  expense  for  interest  and  penalties  in  income  tax  expense, respectively.", "Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions.", "With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.", "We  are  a  party  to  a  tax  matters  agreement  with  CareFusion Corporation  (\"CareFusion\"),  which  has  been  acquired  by  Becton, Dickinson  and  Company.  Under  the  tax  matters  agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction  taxes  prior to our fiscal  2010 spin-off  of  CareFusion.  The indemnification receivable was $72 million and $176 million at June 30, 2021  and  2020,  respectively,  and  is  included  in  other  assets  in  the consolidated balance sheets.", "As  a  result  of  the  acquisition  of  the  Patient  Recovery  Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction  taxes  related to periods  prior  to the acquisition  under the purchase  agreement.  The  indemnification  receivable  was  $12  million and  $19  million  at  June  30,  2021  and  2020,  respectively,  and  is included in other assets in the consolidated balance sheets. 9.", "Assets  and  liabilities  held  for  sale  of  $1.1  billion  and  $96  million, respectively, at June 30, 2021 are primarily related to the divestiture of our  Cordis  business.  These  estimated  fair  values  utilized  Level  3 unobservable  inputs  based  on  expected  sales  proceeds  following  a competitive  bidding  process.  See Note  2 for  additional  information regarding assets and liabilities held for sale.", "We do not use derivative  instruments  for  trading  or  speculative  purposes.  While  the majority  of  our  derivative  instruments  are  designated  as  hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments.", "These derivative  instruments  are  adjusted  to  current  fair  value  through earnings  at  the end of  each  period.  We are exposed to counterparty credit  risk  on  all  of  our  derivative  instruments.  Accordingly,  we  have established and maintain strict counterparty credit guidelines and only enter  into  derivative  instruments  with  major  financial  institutions  that are  rated  investment  grade  or  better.  We  do  not  have  significant exposure  to  any  one  counterparty  and  we  believe  the  risk  of  loss  is remote.  Additionally,  we  do  not  require  collateral  under  these agreements.", "Interest Rate Risk Management We are exposed to the impact of interest rate changes.", "Our objective is to manage the impact of interest rate changes on cash flows and the market  value  of  our  borrowings.  We  utilize  a  mix  of  debt  maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates.", "In addition, we enter into interest rate swaps to further manage  our  exposure  to  interest  rate  variations  related  to  our borrowings and to lower our overall borrowing costs.", "Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange", "rates.  Our  objective  is  to  reduce  earnings  and  cash  flow  volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations.", "Accordingly, we enter into various  contracts  that  change  in  value  as  foreign  exchange  rates change  to  protect  the  value  of  existing  foreign  currency  assets  and liabilities, commitments  and anticipated  foreign currency  revenue and expenses.", "Our objective is to reduce earnings and cash flow volatility associated with forecasted  purchases  of  these  commodities  to  allow  management  to focus its attention on business operations.", "Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.", "The  following  table  summarizes  the  fair  value  of  our  assets  and liabilities related to derivatives designated as hedging instruments and the  respective  line  items  in  which  they  were  recorded  in  the consolidated balance sheets at June 30:", "Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the  fair  value  of  fixed-rate  debt  resulting  from  fluctuations  in  interest rates.", "During fiscal 2021, 2020 and 2019 there was  no  gain  or  loss  recorded  to  interest  expense  as  changes  in  the market value of our derivative instruments offset changes in the market value of the underlying debt.", "During  fiscal  2021,  we  unwound  certain  interest  rate  swap  contracts with the notional amount of $550 million.", "In connection with the unwind of these contracts, we received cash proceeds of", "The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.", "During  fiscal  2021,  we  entered  into  a  pay-floating  interest  rate  swap with  total  notional  amounts  of  $200  million.  This  swap  has  been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.", "In  May  2020,  we  unwound  certain  interest  rate  swap  contracts.  In connection  with  the  unwind  of  these  contracts,  we  received  cash proceeds of $112 million.", "The related gain will be recognized in interest expense,  net  in  our  statements  of  earnings/(loss)  over  the  remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.", "During fiscal 2019, we terminated notional amounts of $163 million of pay-floating  interest  rate  swaps  in  connection  with  the  debt repurchases  in  fiscal  2019  described  in Note  6.  These  swaps  were previously designated as fair value hedges.", "Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in  cash  flows  attributable  to  interest  rate,  foreign  currency  and commodity  price  fluctuations  associated  with  certain  forecasted transactions.", "During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but", "not  firmly  committed,  future  transactions  associated  with  our  debt.", "During  fiscal  2021,  we  terminated  these  swaps  and  reclassified  an immaterial deferred gain from accumulated other comprehensive loss into  interest  expense,  net  in  our  consolidated  statements  of earnings/(loss) because the forecasted transactions were probable of not occurring.", "All  gains  and  losses  currently  included  within  accumulated  other comprehensive  loss  associated  with  our  cash  flow  hedges  that  are expected to be reclassified into net earnings within the next 12 months are immaterial.", "We  enter  into  foreign  currency  contracts  to  protect  the  value  of anticipated foreign currency revenues and expenses.", "At June 30, 2021 and  2020,  we  held  contracts  to  hedge  probable,  but  not  firmly committed,  revenue  and  expenses.  The  principal  currencies  hedged are  the  Chinese  renminbi,  Canadian  dollar,  euro,  Thai  baht  and Mexican peso.", "Net Investment Hedges We  hedge  the  foreign  currency  risk  associated  with  certain  net investment  positions  in  foreign  subsidiaries.  To  accomplish  this,  we enter into cross-currency swaps that are designated as hedges of net investments.", "In  August  2019,  we  entered  into  a  \u00a564  billion  ($600  million)  cross- currency swap maturing in 2022.", "In September 2018, we entered into a \u20ac200 million ($233 million) cross- currency swap maturing in 2023.", "To the  extent  the  cross-currency  swaps  designated  as  net  investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.", "Economic (Non-Designated) Hedges We  enter  into  foreign  currency  contracts  to  manage  our  foreign exchange  exposure  related  to  sales  transactions,  intercompany financing  transactions  and  other  balance  sheet  items  subject  to revaluation  that  do  not  meet  the  requirements  for  hedge  accounting treatment.  Accordingly,  these  derivative  instruments  are  adjusted  to current market value at the end of each period through earnings.", "The  following  table  summarizes  the  estimated  fair  value  of  our  long- term  obligations  and  other  short-term  borrowings  compared  to  the respective carrying amounts at June 30:", "The  fair  value  of  our  long-term  obligations  and  other  short-term borrowings is estimated based on either the quoted market prices for the  same  or  similar  issues  or  other  inputs  derived  from  available market information, which represents a Level 2 measurement.", "The  following  table  is  a  summary  of  the  fair  value  gain/(loss)  of  our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:", "Holders of common shares are entitled to share equally  in  any  dividends  declared  by  the  Board  of  Directors  and  to participate  equally  in  all  distributions  of  assets  upon  liquidation.", "We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as  described  below.  We  funded  the  repurchases  with  available  cash and short term borrowings.", "During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million.", "During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million.", "During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million.", "We do not allocate the following items to our segments:", "\u2022 litigation  (recoveries)/charges,  net;  in  connection  with  the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;", "Because  approval  for  these  projects  is  dependent  on  executive management,  we  retain  these  expenses  at  Corporate.  Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.", "We  maintain  stock  incentive  plans  (collectively,  the  \u201cPlans\u201d)  for  the benefit of certain of our officers, directors and employees.", "Stock Options Until the end of fiscal 2018, stock options were granted to our officers and  certain  employees.  There  were  no  stock  options  granted  to employees  during  fiscal  year  2021,  2020  or  2019.  Employee  stock options  granted  under  the  Plans  generally  vest  in  equal  annual installments over three years and are exercisable for a period up to ten years from the grant date.", "All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.", "The  fair  values  were  estimated  on  the  grant  date  using  a  lattice valuation  model.  We  believe  the  lattice  model  provides  reasonable estimates  because  it  has  the  ability  to  take  into  account  individual exercise  patterns  based  on  changes  in  our  stock  price  and  other variables, and it provides for a range of input assumptions, which are disclosed  in  the  table  below.  The  risk-free  rate  is  based  on  the  U.S.", "Treasury  yield  curve  at  the  time  of  the  grant.  We  analyzed  historical data to estimate option exercise behaviors and employee terminations to  be  used  within  the  lattice  model.  The  expected  life  of  the  options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding.  Expected  volatilities  are  based  on  implied  volatility  from traded  options  on  our  common  shares  and  historical  volatility  over  a period  of  time  commensurate  with  the  contractual  term  of  the  option grant (up to ten years).", "Employee Retirement Savings Plans Substantially all of our domestic non-union employees are eligible to be enrolled  in  our  company-sponsored  contributory  retirement  savings plans,  which  include  features  under  Section  401(k)  of  the  Internal Revenue  Code  of  1986,  and  provide  for  matching  and  discretionary contributions  by  us.  The  total  expense  for  our  employee  retirement savings  plans  was  $55  million,  $66  million  and  $99  million  for  fiscal 2021, 2020 and 2019, respectively.", "The sum of the components may not equal the total due to rounding.", "We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees.", "As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.", "The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our \u201c2021 Proxy Statement\u201d) under the captions \u201cCorporate Governance\u201d and \u201cShare Ownership Information.\u201d", "We consent to the incorporation by reference in the following Registration Statements: (1)    Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc., (2)    Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and (3)     Registration  Statements  on  Form  S-8  No.  33-42357,  No.  333-90423,  No.  333-38192,  No.  333-38198,  No.  333-56010,  No.  333-129725,", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "The  registrant\u2019s  other  certifying  officer(s)  and  I  have  disclosed,  based  on  our  most  recent  evaluation  of  internal  control  over  financial reporting, to the registrant\u2019s auditors and the audit committee of the registrant\u2019s board of directors (or persons performing the equivalent functions):", "Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the \u201c2021 Form 10-K\u201d), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement  is  first  made)  about  future  events,  prospects,  projections  or  financial  performance.  The  matters  discussed  in  these  forward-looking statements  are  subject  to  certain  risks  and  uncertainties  that  could  cause  actual  results  to  differ  materially  from  those  projected,  anticipated  or implied in or by such statements.", "\u2022 risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S.", "House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under  the  Tax  Act;  the  possibility  that  we  may  receive  additional  negative  or  unfavorable  publicity  or  that  the  IRS  may  not  agree  with  our underlying assumptions and judgments;", "\u2022 the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;", "Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws; \u2022 risks  arising  from  our  collecting,  handling  and  maintaining  patient-identifiable  health  information  and  other  sensitive  personal  and  financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;", "\u2022 changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications; \u2022 material  reductions  in  purchases,  pricing  changes,  non-renewal,  early  termination,  or  delinquencies  or  defaults  under  contracts  with  key customers; \u2022 unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix; \u2022 risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;", "\u2022 our ability to introduce and market new products and our ability to keep pace with advances in technology; \u2022 significant charges to earnings if goodwill or intangible assets become impaired; \u2022 uncertainties relating to general political, business, industry, regulatory and market conditions; and \u2022 other factors described in the \u201cRisk Factors\u201d section of the 2021 Form 10-K.", "The words \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201clikely,\u201d and similar expressions generally identify \u201cforward-looking statements,\u201d which speak only as of the date the statements were made, and also include statements reflecting future  results  or  guidance,  statements  of  outlook  and  expense  accruals.  We  undertake  no  obligation  to  update  or  revise  any  forward-looking statements, except to the extent required by applicable law."], "Governance": ["We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;", "We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency.", "We manage our business and report our financial results in two segments: Pharmaceutical and Medical.", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "In addition to distributing Cardinal Health branded products, this segment also  distributes  a  broad  range  of  medical,  surgical  and  laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories  and  other  healthcare  providers  in  the  United  States  and Canada.  This  segment  also  distributes  medical  products  to  patients' homes  in  the  United  States  through  our  Cardinal  Health  at-Home Solutions division.", "Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19,  also  had  an  adverse  impact.  These  factors  were  partially  offset  by  the  beneficial  impact  of  enterprise-wide  cost-savings  measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision  Health  Solutions.  While  fiscal  2021  volumes  within  our  generics  program  were  lower  than  levels  prior  to  COVID-19,  the  impact  on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021.", "Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19.", "The peak of this heightened demand was during the second and third quarters of fiscal 2021.", "This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments.", "During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022.", "Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit.", "Higher volumes in our laboratory business and cost savings positively  impacted  Medical  segment  profit.  Additionally,  despite  declining  customer  demand  and  selling  prices  in  some  categories  of  PPE  as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories.", "In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million.", "The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit.", "The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit  in fiscal 2021 due to volume  declines in our generics  program,  including the impact  of  COVID-19.  The Pharmaceutical  segment  generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture (\"Red Oak Sourcing\") with CVS Health Corporation (\"CVS Health\").", "The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.", "In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities.  While  we  are  taking  actions  to  mitigate  the  impact  of  these  and  other  sourcing  cost  increases  primarily  through  cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.", "Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems.", "Medical Segment Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.", "Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes  in  our  laboratory  business.  For  additional  information  regarding  inventory  reserves,  see  Significant  Developments  in  Fiscal  2021  and Trends section in this MD&A.", "While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.", "Pharmaceutical Segment Profit Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID- 19, partially offset by higher contribution from branded pharmaceutical sales mix.", "Medical Segment Profit Fiscal  2021  Medical  segment  profit  decreased  largely  due  to  the  adverse  impact  of  COVID-19,  which  primarily  includes  an  inventory  reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business.", "Restructuring and Employee Severance In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of  our  Cordis  business.  In  fiscal  2020,  restructuring  costs  were  primarily  related  to  the  implementation  of  certain  enterprise-wide  cost-savings measures.", "fluctuating working capital needs driven by customer and product mix.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "LIFO Inventory A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  are  primarily merchandise  inventories  at  the  core  pharmaceutical  distribution facilities  within  our  Pharmaceutical  segment  (\u201cdistribution  facilities\u201d).", "We  believe  that  the  average  cost  method  of  inventory  valuation provides  a  reasonable  approximation  of  the  current  cost  of  replacing inventory within these distribution facilities.", "Our reporting units are: Pharmaceutical operating segment (excluding our  Nuclear  and  Precision  Health  Solutions  division);  Nuclear  and Precision  Health  Solutions  division;  Medical  operating  segment (excluding our Cardinal Health", "Excess and Obsolete Inventory We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We maintain a hedging program to manage volatility related to some of these market exposures which  employs  operational,  economic,  and  derivative  financial  instruments  in  order  to  mitigate  risk.  See Note  1 and Note  10 of  the  \u201cNotes  to Consolidated Financial Statements\u201d for further discussion regarding our use of derivative instruments.", "As  part  of  our  risk  management  program,  we  perform  sensitivity analysis  on  our  forecasted  direct  commodity  exposure  for  the upcoming  fiscal  year.  Our  forecasted  direct  commodity  exposure  at June 30, 2021 increased approximately $4 million from June 30, 2020.", "We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.", "Pharmaceutical Distribution Our  Pharmaceutical  Distribution  division\u2019s  gross  margin  includes margin  from  our  generic  pharmaceutical  program,  from  distribution services agreements with branded pharmaceutical manufacturers and from  over-the-counter  healthcare  and  consumer  products.  It  also includes manufacturer cash discounts.", "Our  Medical  segment  manufactures  and  sources  Cardinal  Health branded  general  and  specialty  medical,  surgical  and  laboratory products  and  devices.  These  products  include  exam  and  surgical gloves;  needle,  syringe  and  sharps  disposal;  compression;", "incontinence;  nutritional  delivery;  wound  care;  single-use  surgical drapes,  gowns  and  apparel;  fluid  suction  and  collection  systems; urology;  operating  room  supply;  and  electrode  product  lines.  Our Cardinal Health Brand products are sold directly or through third-party distributors  in  the  United  States,  Canada,  Europe,  Asia  and  other markets.", "Acquisitions We have acquired  a number  of  businesses  over  the years  that  have enhanced  our  core  strategic  areas  of  Cardinal  Health  Brand  medical products,  generic  pharmaceutical  distribution  and  services,  specialty pharmaceutical  products  and  services,  international  and  post-acute care.  We  expect  to  continue  to  pursue  additional  acquisitions  in  the future.", "During the last five fiscal years, we completed several acquisitions.", "Divestitures Over  the  past  five  fiscal  years,  we  have  also  completed  several divestitures.", "We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described  in  Note  7  of  the  Notes  to  the  Consolidated  Financial Statements.  We  acquired  the  Cordis  business  from  Johnson  & Johnson for $1.9 billion in October 2015.", "Our largest customers, CVS and OptumRx, accounted for 26 percent and  15  percent  of  our  fiscal  2021  revenue,  respectively.  In  the aggregate,  our  five  largest  customers,  including  CVS  and  OptumRx, accounted for 50 percent of our fiscal 2021 revenue.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We  have  agreements  with  group  purchasing  organizations  (\u201cGPOs\u201d) that act as agents to negotiate vendor contracts on", "Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier\u2019s products accounted for approximately 7 percent of revenue.", "We  operate  in  a  highly  competitive  environment  in  the  distribution  of pharmaceuticals and consumer healthcare products.", "We also operate in  a  highly  competitive  environment  in  the  manufacturing  and distribution of medical devices and surgical products.", "We compete on many  levels,  including  price,  service  offerings,  support  services, customer  service,  breadth  of  product  lines  and  product  quality  and efficacy.", "In  the  Pharmaceutical  segment,  we  compete  with  wholesale distributors  with  national  reach,  including  McKesson  Corporation  and AmerisourceBergen  Corporation,  regional  wholesale  distributors,  self- warehousing  chains,  specialty  distributors,  third-party  logistics", "Employees We, through our employees, improve the lives of people every day by solving  complex  healthcare  problems.  As  of  June  30,  2021,  we  had approximately  47,300  employees  globally,  approximately  18,300  of whom are based outside the United States.", "Approximately 98% of our workforce  is  full  time  employees.  Approximately  29,000  of  our employees  worked  in  our  distribution  centers,  manufacturing  facilities and  pharmacies,  and  18,300  worked  in  other  functions,  including finance, information technology, human resources and sales.", "Approximately  3,230  employees  were  primarily  associated  with  our Cordis business and were transferred in the divestiture in August 2021.", "Additionally,  we  have  engaged  global  professional  services  firms  to perform  certain  business  processes  on  our  behalf,  including  within finance, information technology and human resources.", "Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc.", "Sales to members of these  two  GPOs,  under  numerous  contracts  across  our  businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.", "We also compete with manufacturers that sell their products directly.", "In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries,  Inc.,  Owens  &  Minor,  Inc.  and  Becton,  Dickinson  and Company,  as  well  as  regional  medical  product  distributors  and companies  that  are  focused  on  specific  product  categories.  We  also compete  with  companies  that  distribute  medical  products  to  patients' homes and third-party logistics companies.", "Diversity, Equity & Inclusion At Cardinal Health, we are focused on building a diverse workforce and an  inclusive  workplace  that  values  the  unique  perspectives  and contributions of all of our employees.", "We  promote  a  culture  of  diversity,  equity  and  inclusion  through,  for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women.", "They are designed  to  foster  an  inclusive  and  engaged  workforce  and  develop future  leaders.  In  addition,  we  have  manager  and  broad-based unconscious bias and racial equity training courses.", "Our work is led by our  senior  executives  with  advice  from  a  Diversity  and  Inclusion Steering  Council  which  consists  of  senior  leaders  from  across  the company.  Additionally,  in  December  2019,  we  created  a  new  African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.", "We  have  established  long-range  aspirational  representation  goals  for specific  under-represented  groups  in  our  manager-and-above  level employee population.", "Employee Health & Safety The health, safety and security of our employees is an priority for us.", "We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks.", "We routinely assess facilities to closely monitor adherence to  established  security  and  safety  standards.  Our  employees  receive specialized  training  related  to  their  role,  work  setting,  and  equipment used in their work environment.  As our processes evolve, we update relevant  safety  training  modules,  which  may  include  new  employee training programs.", "COVID-19 Response Protecting  the  health  and  safety  of  our  employees  and  their  families has been a priority throughout the COVID-19 pandemic.", "In March, 2020, all employees who could work remotely began working from  home.  We  expanded  our  technology  infrastructure  to  help employees  perform  their  duties  remotely  and  continue  to  support customers,  patients  and  our  frontline  colleagues.  Many  of  these employees continue to work remotely.", "Because  Cardinal  Health  is  part  of  a  critical  infrastructure  industry, more than 30,000 of our employees have continued to report to work in distribution  centers,  supply  chain  operations,  manufacturing  sites, pharmacies and other clinical sites.", "To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and  we  implemented  safety  measures,  including  mask  and  social distancing requirements, in accordance with the U.S.", "We  rely  on  a  combination  of  trade  secret,  patent,  copyright  and trademark  laws,  nondisclosure  and  other  contractual  provisions,  and technical  measures  to  protect  our  products,  services  and  intangible assets.  We  hold  patents,  and  continue  to  pursue  patent  protection throughout the world, relating to the manufacture, operation and use of various  medical  and  surgical  products,  to  certain  distribution  and logistics  systems,  to  the  production  and  distribution  of  our  nuclear pharmacy  products  and  to  other  service  offerings.  We  also  operate under  licenses  for  certain  proprietary  technologies,  and  in  certain instances we license our technologies to third parties.", "Centers  for  Disease  Control  and  Prevention  and  the  World  Health Organization  guidelines.  We  also  educated  employees  on  how  they can  help  keep  themselves  and  their  families  safe  and  have  training programs  to  help  employees  stay  safe  in  their  jobs.  Our  safety measures have helped us to avoid a wide spread outbreak of COVID- 19 among our employees.", "Talent Retention & Culture Talent Development and Learning Cardinal  Health\u2019s  talent  development  strategy  is  a  segmented,  multi- pronged  approach  to  build  capabilities,  skills  and  competencies  of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes.", "Culture Cardinal  Health\u2019s  culture  is  rooted  in  our  values  and  behaviors  and aligned  to  the  company\u2019s  strategic  framework.  Providing  a  positive work environment supports our ability to attract, retain and develop our employees and enables business performance.", "We reinforce, monitor and assess our culture through a variety of programs and processes which  include  performance  management,  talent/succession  planning, employee engagement surveys and other listening strategies.", "While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark,  license,  franchise  or  concession  to  be  material  to  our overall business.", "Our  business  is  highly  regulated  in  the  United  States,  at  both  the federal and state level, and in foreign countries.", "These  regulatory  agencies  have  a  variety  of  civil,  administrative  and criminal sanctions at their disposal for failure to comply with applicable legal  or  regulatory  requirements.  They  can  suspend  our  ability  to manufacture  and  distribute  products,  require  us  to  initiate  product recalls,  seize  products  or  impose  criminal,  civil  and  administrative sanctions.", "Manufacturing, Sourcing and Marketing We  sell  our  manufactured  products  in  the  United  States,  Canada, Europe,  Asia,  Latin  America  and  other  markets.  The  FDA  and  other governmental  agencies  in  the  United  States,  as  well  as  foreign governmental agencies, administer requirements that cover the design, testing,  safety,  effectiveness,  manufacturing  (including  good", "manufacturing  practices),  quality  systems,  labeling,  promotion  and advertising (including restrictions on promoting or advertising a product other  than  for  the  product's  cleared  or  approved  uses),  distribution, importation and post-market surveillance for most of our manufactured products.", "We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.", "In  the  United  States,  authorization  to  commercially  market  a  medical device  is  generally  received  in  one  of  two  ways.  The  first,  known  as pre-market  notification  or  the  510(k)  process,  requires  us  to demonstrate  that  a  medical  device  is  substantially  equivalent  to  a legally marketed  medical device.  The second more rigorous  process, known  as  pre-market  approval  (\u201cPMA\u201d),  requires  us  to  independently demonstrate that a medical device is safe and effective.", "Many of our Medical  segment  branded  products  are  cleared  through  the  510(k) process  and  certain  products  must  be  approved  through  the  PMA process.", "In the EU, we are required to obtain CE Mark Certification in order to market medical devices.", "It  can  be  costly  and  time-consuming  to  obtain  regulatory  approvals, clearances and registrations of medical devices, and they might not be granted  on  a  timely  basis,  if  at  all.  Even  after  we  obtain  approval  or clearance  to  market  a  product  or  obtain  product  registrations,  the product  and  our  manufacturing  processes  are  subject  to  continued regulatory  oversight,  including  periodic  inspection  of  manufacturing facilities  by  FDA  and  other  regulatory  authorities  both  in  the  United States and internationally.", "From time to time, we may determine that products we manufacture or market  do  not  meet  our  specifications,  regulatory  requirements  or published standards.", "When we or a regulatory agency identify a quality or  regulatory  issue,  we  investigate  and  take  appropriate  corrective action, which may include recalling the product, correcting the product at  the  customer  location,  revising  product  labeling  and  notifying customers.", "For example, in January 2020, we issued a voluntary recall for certain surgical gowns and", "two  voluntary  field  actions  for  certain  Presource  Procedure  Packs because  one  of  our  FDA-registered  suppliers  in  China  had  shifted production of some gowns to unapproved sites.", "Any adverse regulatory action, depending on its magnitude, may limit our  ability  to  effectively  manufacture,  source,  market  and  sell  our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations.", "Nuclear Pharmacies and Related Businesses Our  nuclear  pharmacies  and  radiopharmaceutical  manufacturing facilities  (including  for  Xofigo)  require  licenses  or  permits  and  must abide  by  regulations  issued  by  the  NRC,  applicable  state  boards  of pharmacy and the radiologic health agency or department of health of each  state  in  which  we  operate,  including  pharmacy  sterile compounding  standards  and  practices.  In  addition,  our", "The first phase of  implementation  began  in  2015,  and  upon  full  implementation  in 2023,  we  and  other  supply  chain  stakeholders  will  participate  in  an electronic, interoperable, prescription drug tracing system.", "Laws Relating to Foreign Trade and Operations U.S. and foreign laws require us to abide by standards relating to the import  and  export  of  finished  goods,  raw  materials  and  supplies  and the handling of information.", "We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations  for  transactions  within  some  countries  or  with  some counterparties.", "Although our agreements with manufacturers sometimes require us to maintain  inventory  levels  within  specified  ranges,  our  distribution businesses  are  generally  not  required  by  our  customers  to  maintain particular inventory levels other than as needed to meet service level requirements.  Certain  customer  contracts  require  us  to  maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.", "Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.", "COVID-19 Risks We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.", "See the description of the actual and possible effects of the COVID-19 pandemic  and  resulting  disruptions  on  our  business  and  operations discussed  above  in  \u201cManagement\u2019s  Discussion  and  Analysis  of Financial  Condition  and  Results  of  Operations.\u201d  In  addition  to  the adverse  impacts  and  uncertainties  from  the  COVID-19  pandemic identified  there,  we  continue  to  face  additional  possible  adverse impacts, including those described below.", "During  the  COVID-19  pandemic,  our  Medical  segment  experienced dramatically  increased  demand  for  and  industry  shortages  of  certain PPE,  such  as  masks,  gowns  and  gloves.  This  increased  demand resulted in increased costs to manufacture and source these products, and  ultimately,  higher  inventory  levels.  As  a  result,  we  have  sought additional  sources  for  these  products  and  to  mitigate  the  cost increases,  we  have  raised  our  selling  prices  for  affected  products.", "During  the  fourth  quarter  of  fiscal  year  2021,  selling  prices  and customer  demand  for  certain  PPE  declined,  which  we  expect  to continue into fiscal year 2022.", "Our estimates  for demand and selling prices  are inherently  uncertain and if demand or selling prices or other market dynamics decline in the future  beyond  our  current  assumptions,  additional  inventory  reserves may be required, which would adversely impact Medical segment profit.", "Within  our  Pharmaceutical  segment,  COVID-19-related  volume declines  have  negatively  impacted  our  Pharmaceutical  segment generics program, but are expected to moderate in fiscal year 2022.", "If demand for these products does not return to pre-COVID-19 levels, or returns  more  slowly  than  anticipated,  the  negative  impact  could  be more prolonged or significant than we currently expect.", "Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or  deferral  of  many  elective  medical  procedures  and  some  of  our customers  closing  or  severely  curtailing  their  operations.  While  lower demand  for  surgical  products  resulting  from  reduced  elective procedures  had  an  adverse  impact  on  Medical  segment  profit  during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021.", "governmental policies designed to reduce the transmission of COVID- 19  return  and  demand  for  these  procedures  does  not  increase  or decreases  further,  we could have less sales of the affected  products and services than we currently expect.", "Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.", "We cannot estimate the continued length or severity of the COVID-19 pandemic  or  the  related  consequences  on  the  U.S.  and  global economy  and  our  business  and  operations,  including  whether  and when  normal  economic  and  operating  conditions  will  resume  or  the extent  to  which  further  disruption  may  impact  our  business,  financial position, results of operations or cash flow.", "A significant number of states, counties, municipalities and other public plaintiffs,  have  filed  lawsuits  against  pharmaceutical  manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others  relating  to  the  manufacturing,  marketing  or  distribution  of prescription opioid pain medications.", "Ongoing  unfavorable  publicity  regarding  the  abuse  or  misuse  of prescription  opioid  pain  medications  and  the  role  of  wholesale distributors in the supply chain of such prescription medications, as well as  the  continued  proliferation  of  the  opioid  lawsuits,  investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.", "Our business is subject to other rigorous quality, regulatory and licensing requirements.", "concerns over noncompliance, including noncompliance by third-party contract  manufacturers,  may  result  in  suspension  of  our  ability  to distribute, import, manufacture or source products, as well as product bans,  recalls,  safety  alerts  or  seizures,  or  criminal  or  civil  sanctions, which,  in  turn,  could  result  in  product  liability  claims  and  lawsuits, including class actions.", "It is also possible that these regulatory actions could  adversely  impact  our  ability  to  procure  products  to  distribute, resulting in increased costs or industry supply disruptions.", "Our  government  contracts  are  subject  to  specific  procurement requirements.", "Our global operations (including transition services in connection with divestitures)  are  subject  to  the  U.S.  Foreign  Corrupt  Practices  Act (\"FCPA\"),  the  U.K.  Bribery  Act  and  similar  anti-bribery  laws  in  other jurisdictions  and  U.S.  and  foreign  export  control,  trade  embargo  and customs laws.", "We are a large multinational corporation with operations in the United States and many foreign countries.", "Over a number of years, the U.S. healthcare industry has undergone significant  changes  designed  to  increase  access  to  medical  care, improve  safety  and  patient  outcomes,  contain  costs  and  increase efficiencies.", "We  expect  the  U.S.  healthcare  industry  to  continue  to  change significantly in the future.", "Due  to  the  nature  of  our  business,  which  includes  the  distribution  of controlled  substances  and  other  pharmaceutical  products  and  the sourcing,  marketing  and  manufacturing  of  medical  products,  we regularly become involved in disputes, litigation and regulatory matters.", "Our business and operations depend on the proper functioning of information  systems,  business  processes,  critical  facilities  and distribution networks.", "We rely on our and third-party service providers' information systems for  a  wide  variety  of  critical  operations,  including  to  obtain,  rapidly process, analyze and manage data to: \u2022 facilitate  the  purchase  and  distribution  of  inventory  items  from", "Our  business  also depends on the  proper  functioning  of  our and our suppliers'  business  processes,  critical  facilities,  including  our  national logistics center, and our distribution networks.", "Our results of operations could  be  adversely  affected  if  our  or  a  service  provider's  business processes,  information  systems,  critical  facilities  or  distribution networks are disrupted (including disruption of access), are damaged or  fail,  whether  due  to  physical  disruptions,  such  as  fire,  natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages,  political  unrest  and  terrorist  attacks.  Manufacturing disruptions also can occur due to regulatory action, production quality deviations,  safety  issues  or  raw  material  shortages  or  defects,  or because  a  key  product  or  component  is  manufactured  at  a  single manufacturing facility with limited alternate facilities.", "From  time  to  time,  our  businesses  perform  business  process improvements or infrastructure modernizations or use service providers for  key  systems  and  processes,  such  as  receiving  and  processing customer  orders,  customer  service  and  accounts  payable.  For example, our Pharmaceutical segment is currently engaged in a multi- year  project  to  implement  a  replacement  of  certain  finance  and operating  information  systems  and  we  recently  transitioned  certain finance  processes  to  a  third-party  service  provider.  If  any  of  these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.", "Our  business  and  results  of  operations  could  be  adversely affected if we experience a cyber-attack or other systems breach.", "Our business relies on the secure transmission, storage and hosting of patient-identifiable  health  information,  financial  information  and  other sensitive  protected  information  relating  to  our  customers,  company, workforce  and  individuals  with  whom  we  and  our  customers  conduct business.", "We have programs in place to detect, contain and respond to information security incidents.", "However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems  change  frequently  and  may  be  difficult  to  detect  for  long periods of time, we may be unable to anticipate these techniques or to implement  adequate  preventative  measures.  In  addition,  hardware, software  or  applications  developed  internally  or  procured  from  third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.", "Unauthorized parties have gained access and will continue to attempt to  gain  access  to  our  or  a  service  provider's  systems  or  facilities through fraud, trickery or other forms of deception.", "We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain  customer  account  information  was accessed.  Although we do not  believe  these  incidents  had  a  material  impact  on  us,  similar incidents or events in the future may negatively impact our business, reputation or financial results.", "Any  compromise  of  our  or  a  service  provider's  information  systems, including  unauthorized  access  to  or  use  or  disclosure  of  sensitive information,  could  adversely  impact  our  operations,  results  of operations  or  our  ability  to  satisfy  legal  or  regulatory  requirements, including the EU general data protection regulation (GDPR) and those related  to  patient-identifiable  health  information  and  other  sensitive personal  and  financial  information  as  further  described  in  the  Risk Factor  titled  \u201cOur  business  is  subject  to  rigorous  regulatory  and licensing requirements,\u201d above.", "CVS  is  a  large  customer  that  generates  a  significant  amount  of  our revenue.", "Our results of operations could be adversely impacted if we fail to manage and complete divestitures.", "We regularly evaluate our portfolio of businesses to determine whether an  asset  or  business  may  no  longer  help  us  meet  our  objectives  or whether there may be a more advantaged owner for", "that  business.  For  example,  we  recently  completed  the  divestiture  of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc.", "When we decide to sell assets  or  a  business,  we  may  encounter  difficulty  finding  buyers  or alternative  exit  strategies,  which  could  delay  the  achievement  of  our strategic objectives.", "Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.", "An important element of our growth strategy has been to acquire other businesses  that  expand  or  complement  our  existing  businesses.", "This testing involves estimates and significant judgments by management.", "Industry & Economic Risks We  could  continue  to  suffer  the  adverse  effects  of  competitive pressures.", "Our businesses face continued pricing pressure from these factors, which adversely affects our margins.", "If we are unable to offset margin  reductions  caused  by  these  pricing  pressures  through  steps such as sourcing or cost control measures, additional service offerings and  sales  of  higher  margin  products,  our  results  of  operations  could continue to be adversely affected.", "Our  Pharmaceutical  segment\u2019s  profit  margin  could  be  adversely affected by changes in industry or market dynamics that we are not able to accurately predict.", "In  fiscal  year  2021,  our  Pharmaceutical  segment\u2019s  generics  program was negatively impacted by volume declines.", "We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs,  availability  and  regulatory  risks  associated  with  these products and raw materials.", "We depend on others to manufacture some products that we market and  distribute.  Our  operations  are  also  dependent  on  various components,  compounds,  raw  materials  and  energy  supplied  by others.  We  purchase  many  of  these  components,  raw  materials  and energy,  and  source  certain  products  from  numerous  suppliers  in various countries.", "In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier.", "Our supplier relationships could be interrupted,  become  less  favorable  to  us  or  be  terminated  and  the supply  of  these  components,  compounds,  raw  materials  or  products could be interrupted or become insufficient.", "These supply interruptions or  other  disruptions  in  manufacturing  processes  could  be  caused  by events beyond our control, including natural disasters, supplier facility shut-downs,  defective  raw  materials,  the  impact  of  epidemics  or pandemics,  such  as  COVID-19,  and  actions  by  U.S.  or  international governments, including export restrictions or tariffs.", "In addition, due to the stringent regulatory requirements regarding the manufacture  and  sourcing  of  our  products,  we  may  not  be  able  to quickly  establish  additional  or  replacement  sources  for  certain components,  materials  or  products.  A  sustained  supply  reduction  or interruption,  and  an  inability  to  develop  alternative  and  additional sources  for  such  supply,  could  result  in  lost  sales,  increased  cost, damage  to  our  reputation,  and  may  have  an  adverse  effect  on  our business.", "Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products.", "Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate.", "Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply  chain  costs,  primarily  related  to  the  sourcing  of  certain components,  compounds,  raw  materials  and  commodities.  Due  to competitive dynamics and contractual limitations, we may be unable to pass  along  cost  increases  through  higher  prices.  If  we  cannot  fully offset  cost  increases  through  other  cost  reductions,  or  recover  these costs through price increases or surcharges, our results of operations could continue to be adversely affected.", "Consolidation  in  the  U.S.  healthcare  industry  may  negatively impact our results of operations.", "Consolidations create larger enterprises with greater negotiating power, and  also  could  result  in  the  possible  loss  of  a  customer  where  the combined enterprise selects one distributor from two incumbents.", "If this consolidation  trend  continues,  it  could  adversely  affect  our  results  of operations.", "We conduct our operations in various regions of the world outside of the  United  States,  including  Europe,  Asia  and  Latin  America.  Global developments  can  affect  our  business  in  many  ways.  Our  global operations  are  affected  by  local  economic  environments,  including inflation,  recession  and  competition.  Additionally,  divergent  or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.", "We may be required to spend more money to source  certain  products  or  materials  that  we  need  or  to  manufacture certain of our products.", "This could adversely impact our business and results of operations.", "At June 30, 2021, our Medical segment also operated manufacturing facilities  in  Canada,  Costa  Rica,  the  Dominican  Republic,  Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.", "Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.", "We consider our operating properties to be in satisfactory condition and adequate to meet our present needs.", "However, we regularly evaluate operating  properties  and  may  make  further  additions  and", "improvements  or  consolidate  locations  as  we  seek  opportunities  to expand or enhance the efficiency of our business.", "During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022.", "We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company\u2019s goodwill  impairment  review  process.  For  example,  we  tested  controls  over  management\u2019s  review  of  significant  judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions.", "We compared the significant assumptions  used  by  management  to  current  industry  and  economic  trends,  recent  historical  performance,  changes  to  the reporting unit\u2019s business model, customer base or product mix and other relevant factors.", "We evaluated the incorporation of the applicable assumptions  into  the  model  and  tested  the  model\u2019s  computational  accuracy.  In  addition,  we  inspected  the  Company\u2019s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.", "We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management\u2019s evaluation of the product liability litigation reserve.", "We also tested management\u2019s controls over the completeness and accuracy of the data used in the model.", "Cardinal  Health,  Inc.  is  a  globally  integrated  healthcare  services  and products  company  providing  customized  solutions  for  hospitals, healthcare  systems,  pharmacies,  ambulatory  surgery  centers,  clinical laboratories  and  physician  offices.  We  provide  pharmaceuticals  and medical  products  and  cost-effective  solutions  that  enhance  supply chain  efficiency.  References  to  \u201cwe\u201d,  \u201cour\u201d  and  similar  pronouns  in these consolidated financial statements are to Cardinal Health, Inc. and its  majority-owned  or  controlled  subsidiaries  unless  the  context otherwise requires.", "The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.", "Credit  risk  can  be  affected  by  changes  in  reimbursement  and  other economic pressures impacting the healthcare industry.", "These customers are primarily serviced through our Pharmaceutical segment.", "In  August  2021,  we  extended  our  pharmaceutical  distribution agreements with CVS through June 2027.", "We have entered into agreements with group purchasing organizations (\u201cGPOs\u201d)  which  act  as  purchasing  agents  that  negotiate  vendor contracts on behalf of their members.", "Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue.", "Inventories A  portion  of  our  inventories  (50  percent  and  56  percent  at  June  30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in,  first-out  (\"LIFO\")  method,  or  market.  These  inventories  are included  within  the  core  pharmaceutical  distribution  facilities  of  our Pharmaceutical  segment  (\u201cdistribution  facilities\u201d)  and  are  primarily merchandise  inventories.  The  LIFO  method  presumes  that  the  most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue.", "We believe that the average cost  method  of  inventory  valuation  provides  a  reasonable", "Our remaining inventory,  including inventory  in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value.", "Net  realizable  value  is  defined  as  the  estimated  selling  prices  and estimated  sales  demand  in  the  ordinary  course  of  business,  less reasonably  predictable  costs  of  completion,  disposal  and", "We  reserve  for  inventory  obsolescence  using  estimates  based  on historical  experience,  historical  and  projected  sales  trends,", "We  have  two  operating  segments,  which  are  the  same  as  our reportable  segments:  Pharmaceutical  and  Medical.  These  operating segments are comprised of divisions (components), for which discrete financial  information  is  available.  Components  are  aggregated  into reporting units for purposes of goodwill impairment testing to the extent that  they  share  similar  economic  characteristics.  Our  reporting  units are:  Pharmaceutical  operating  segment  (excluding  our  Nuclear  and Precision  Health  Solutions  division);  Nuclear  and  Precision  Health Solutions division; Medical operating segment (excluding our Cardinal Health  at-Home  Solutions  division)  (\u201cMedical  Unit\u201d);  and  Cardinal Health at-Home Solutions division.", "Fair  value  can  be  determined  using  market,  income  or  cost-based approaches.", "Under the market- based  guideline  public  company  method,  we  determine  fair  value  by comparing  our  reporting  units  to  similar  businesses  or  guideline companies whose securities are actively traded in public markets.", "At any given time, there are outstanding items in various stages of research and resolution.", "In determining  appropriate  reserves  for  areas  of  exposure  with  our vendors,  we  assess  historical  experience  and  current  outstanding claims.", "manufactured  and  sourced  products,  and  we  recognize  at  a  point  in time  when  title  transfers  to  customers  and  we  have  no  further obligation  to  provide  services  related  to  such  merchandise.  Service revenues are recognized over the period that services are provided to the  customer.  Revenues  derived  from  services  are  not  material  for either segment for all periods presented.", "Restructuring and Employee Severance Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products,  moving manufacturing  of a product  to another location, changes in production or business process outsourcing or insourcing, employee  severance  (including  rationalizing  headcount  or  other significant changes in personnel)  and realigning operations (including realignment  of  the  management  structure  in  response  to  changing market  conditions).  Also  included  within  restructuring  and  employee severance are", "We  did  not  complete  any  acquisitions  during  fiscal  2020.  While  we completed several small acquisitions during fiscal 2021 and 2019, the pro  forma  results  of  operations  and  the  results  of  operations  for acquired  businesses  since  the  acquisition  dates  have  not  been separately disclosed because the effects were not significant compared to  the  consolidated  financial  statements,  individually  or  in  the aggregate.", "associated  with  restructuring  our  delivery  of  information  technology infrastructure services and certain other divestiture-related costs.", "In  fiscal  2021,  restructuring  costs  were  primarily  related  to  the implementation  of certain enterprise-wide  cost-savings measures and the  divestiture  of  our  Cordis  business.  In  fiscal  2020  and  2019, restructuring  costs  were  primarily  related  to  the  implementation  of certain enterprise-wide cost-savings measures.", "Our  operating  leases  are  primarily  for  corporate  offices,  distribution facilities, vehicles, and equipment.", "From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published  standards.  When  we  or  a  regulatory  agency  identify  a potential  quality  or  regulatory  issue,  we  investigate  and  take appropriate corrective action.", "Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.", "From  time  to  time,  we  become  aware  through  employees,  internal audits  or  other  parties  of  possible  product  quality,  regulatory  or compliance  matters,  such  as  complaints  or  concerns  relating  to accounting, internal accounting controls, financial reporting, auditing, or other  ethical  matters  or  relating  to  compliance  with  laws  such  as healthcare fraud and abuse, anti-corruption or anti-bribery laws.", "In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a  customer,  supplier  or  other  industry  participants.  Internal", "In addition, we and the two other settling  distributors  will  engage  a  third-party  vendor  to  act  as  a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.", "SEC Investigation In  February  2021,  we  received  a  subpoena  from  the  U.S.  Securities and  Exchange  Commission  requesting  the  production  of  documents from  2015  through  2019  relating  to  inventory  in  the  Cordis  business, analysis of goodwill of the Medical segment and other matters.", "We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General.", "We  utilize  derivative  financial  instruments  to  manage  exposure  to certain  risks  related  to  our  ongoing  operations.  The  primary  risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk.", "Commodity Price Risk Management We are exposed to changes in the price of certain commodities.", "We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.", "Our  operations  are  principally  managed  on  a  products  and  services basis  and  are  comprised  of  two  operating  segments,  which  are  the same  as  our  reportable  segments:  Pharmaceutical  and  Medical.  The factors for determining the reportable segments include the manner in which management  evaluates performance  for purposes  of allocating resources and assessing performance combined with the nature of the individual business activities.", "Revenue Our  Pharmaceutical  segment  distributes  branded  and  generic pharmaceutical,  specialty  pharmaceutical  and  over-the-counter", "Our Medical segment manufactures, sources and distributes Cardinal Health  branded  medical,  surgical  and  laboratory  products,  which  are sold in the United States, Canada, Europe, Asia and other markets.", "This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.", "Segment Profit We  evaluate  segment  performance  based  on  segment  profit,  among other measures.", "Ms.  Holcomb  has  served  as  Executive  Vice  President,  Strategy  and  Corporate  Development  since  January  2017.  She  joined  us  from  Teva Pharmaceutical  Industries  Ltd.,  where  she  served  as  Senior  Vice  President,  Strategy,  Portfolio,  Search,  and  Partnerships  and  Chief  Operating Officer, Global R&D from October 2015 to December 2016.", "The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation.", "These risks and uncertainties include: \u2022 risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases  in  demand  or  selling  price;  the  risk  that  we  may  not  be  able  to  offset  significant  cost  increases  for  certain  personal  protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;", "\u2022 risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations; \u2022 uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business; \u2022 risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;"]}